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It has been well documented that coronary vasoconstriction, atheroma plaque burden, 
and ‘vulnerable’ plaque plays a critical role in the pathogenesis of acute coronary 
syndrome (ACS); yet, the dynamic interaction among these factors in vivo to date have 
not been evaluated, particularly in the longitudinal study. In this thesis, we described a 
series of in vivo experiments conducted within the intact epicardial coronary tree from 
patients who presented with unselected clinical presentation, with the aim to explore the 
underlying relationship between coronary atheroma burden, plaque composition, and 
coronary endothelial vasoreactive function. We particularly highlight the potential role 
of a novel intravascular ultrasound (IVUS) platform which co-register with near 
infrared spectroscopy (NIRS) in delineating plaque composition. Utilizing this 
technology allows us to examine the evolution of both grey scale measurement and 
coronary plaque composition over time. Contrary to currently available imaging 
platforms for plaque composition, such as virtual histology IVUS or optical coherence 
tomography (OCT) which is predominantly qualitative, NIRS measurements are 
automated and quantitative, allowing ready interpretation in the catheterization lab. 
 
Of the 2 introductory chapters, chapter 1 explores the developmental history, clinical 
indication, and research application of IVUS in the past three decades. Chapter 2 
reviews the different resistance compartments of the coronary tree and the role of 
various pharmacological agent in the catheterization lab. This chapter also discusses the 
role of salbutamol in the evaluation of coronary endothelial function. 
 
Chapter 3-5 comprise the result section of this thesis. Chapter 3 describes the 
effectiveness of OCT in the evaluation of epicardial coronary endothelial function. OCT 
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is known to have superior lateral resolution when compared to other intravascular 
imaging modalities currently available. In this chapter, we underscore the limitation of 
OCT, which relies on bolus contrast injection for blood clearance from the field of 
view, in the invasive coronary endothelial function assessment. A vast number of 
coronary vasoreactive agents, including salbutamol, are largely dependent on shear 
stress generated by the microvascular compartment to mediate conduit vessel 
vasodilation. Injection of contrast bolus at high rate hence may increase the shear stress 
generated and impact on the reliability of vasomotor response. 
 
Chapter 4 outlines the relationship between segmental coronary endothelial dependent 
and independent function with atheroma plaque volume and associated lipid rich 
necrotic composition in unselected patients who present with either stable chest pain 
syndrome or ACS. Utilizing NIRS, we demonstrated that coronary endothelial 
independent function in response to glyceryl trinitrate (GTN) was strongly associated 
with atheroma plaque volume irrespective whether the patient presented with stable 
chest pain or ACS. To a lesser extent, we also found a weak association between plaque 
containing lipid rich necrotic core with coronary endothelium independent vasodilator 
function. It was also surprising to note the lack of association between coronary 
endothelial dependent function with either atheroma volume or composition. Having 
reviewed previous data in the literature and scrutinised our findings, we concluded that 
adequate dosing of any vasoreactive agent is crucial to generate the desirable and 
appropriate vasomotor response. 
 
Chapter 5 describes our prospective and serial imaging analysis which aimed to identify 
the relationship between epicardial coronary vasomotor function and change in 
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atheroma plaque volume and necrotic lipid laden core plaque, over time. Several key 
insights emerge from this experiment. We identified that epicardial coronary endothelial 
function seems to influence the progression of plaque volume and its composition in a 
unique manner. Whilst coronary endothelial dependent function was found to mediate 
plaque composition progression, the segmental coronary endothelial independent 
function was more associated with atheroma volume progression. Similar to previous 
observations, we also found baseline plaque burden and positive remodelling to 
influence formation of future fibroatheroma. Furthermore, baseline NIRS derived LCBI 
was independently predictive of both lipid core progression and plaque volume 
progression. Taken together, these findings underline the role of atheroma structure-
vessel function in mediating the mechanism of atheroma plaque progression in intact 
human epicardial coronary tree and may provide an important prognostic tool in 
identifying patients who are at risk of developing future coronary event above and 
beyond the established cardiovascular risk predictive tools. 
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ABSTRACT 
For the last 60 years, coronary angiography remains the investigation of choice to 
evaluate symptomatic coronary artery disease. Coronary angiography however only 
provides a two dimensional “luminogram” of a three dimensional arterial structure. As a 
result, its interpretation is subjected to interobserver variability and may be 
compounded by vessel overlapping and tortuosity. Intravascular ultrasound (IVUS), on 
the other hand is a catheter-based technique which provides a comprehensive 
assessment of the entire vessel wall, including the extent and distribution of the 
atherosclerotic plaque. Owing to its high resolution, IVUS has been used extensively in 
various clinical and research settings. Some of the IVUS diagnostic clinical applications 
include assessment of angiographically intermediate lesions, assessment of plaque 
morphology, and evaluating appropriate expansion of an inserted coronary stent. IVUS 
is also extremely valuable in guiding percutaneous revascularisation strategies, 
especially in the case of left main coronary artery disease, allowing for detailed pre-
intervention evaluation of the target artery as well as post intervention assessment of 
procedural outcome. This information is ultimately critical for the clinician to devise an 
appropriate procedural strategy to optimize clinical outcome. In atherosclerosis 
research, IVUS has provided a significant insight into the understanding of the natural 
history of atherosclerosis. The serial IVUS-measured atheroma change has been widely 
used as a surrogate end point in various pharmacological clinical trials. The 
development of new IVUS technology, such as virtual histology IVUS or combined 
IVUS with near infrared spectroscopy has allowed further characterization of 
atherosclerotic plaque to potentially help identify vulnerable plaque, which may provide 
important risk predictive information regarding focal coronary artery disease. 
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I. INTRODUCTION 
Since Mason Sones performed the world’s first diagnostic coronary angiography in 
1958, coronary angiography has been widely used as the standard clinical imaging to 
identify the significance of coronary arterial narrowings and to guide catheter based and 
surgical revascularisation strategies (Mueller and Sanborn, 1995, Topol and Nissen, 
1995). However, despite its excellent ability to visualize the contour of the vascular 
lumen, coronary angiography has some inherent inadequacies and limitations. Among 
others, coronary angiography provides little insight regarding tissue composition, 
atheroma plaque characteristics, as well as its extent and distribution (Nissen, 2001, 
Nicholls and Nissen, 2009). This is not entirely surprising given angiography merely 
produces a two dimensional silhouette of the contrast filled lumen and does not evaluate 
vessel wall, the site in which plaque accumulates. Moreover, coronary angiography is 
subject to significant intraobserver and interobserver variability, raising the issue 
regarding its accuracy and reproducibility in assessing the extent of coronary artery 
disease (Topol and Nissen, 1995, Zir et al., 1976, Murphy et al., 1979, Galbraith et al., 
1978). In fact, major discrepancies between angiographic visual estimation of lesion 
severity and post mortem examination had been reported previously (Roberts and Jones, 
1979, Arnett et al., 1979, Topol and Nissen, 1995). The use of intravascular imaging 
techniques, specifically intravascular ultrasound (IVUS), provides a meticulous 
characterization of vessel wall as well as information regarding the extent and 
distribution of atherosclerotic plaque (Puri et al., 2011). IVUS has also demonstrated 
the ubiquitous presence of plaque in the region which appears normal when assessed 
with coronary angiography (Nissen, 2001). Thus, from a research perspective, IVUS 
provides a unique opportunity to examine the natural history of atherosclerosis in vivo 
along with the impact of specific medical therapies on this process, in addition to its 
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known clinical benefit to guide revascularisation strategy with percutaneous coronary 
intervention (PCI).  
 
History of IVUS 
The first real time catheter ultrasound system designed for intracardiac imaging was 
introduced by Bom et al in the late 1960s (Bom et al., 1972, Yock et al., 1989). The 
transducer for this system was a 32 barium titanate piezoelectric (pressure-electric) 
element circular array mounted at the tip of a 3mm (9F) catheter. Clear images were 
obtainable with this system however limitation with image quality and ring down 
artefact led a number of groups to develop mechanical catheter imaging systems 
(Roelandt et al., 1989, Pandian et al., 1988, Yock et al., 1989). Hodgson et al (Hodgson 
et al., 1989b) then performed the first in vivo IVUS study on 20 patients during cardiac 
catheterization by inserting a 20 MHz transducer through a 0.014” floppy guidewire. 
Since these early times, technological advances in IVUS have included a reduction in 
ultrasound transducer size (0.87-1.17mm) and increasing ultrasound frequency (30-45 
MHz). The result is a high resolution, cross sectional, tomographic image of the entire 
vessel wall resembling histology cross sectional specimen. 
 
Principles of IVUS 
Medical ultrasound images are produced by passing an electrical current through a 
miniaturised crystal that expands and contracts to produce sound waves. The generated 
sound waves then propagate through the different tissue and subsequently reflected 
according to the acoustic properties of the tissue it travels through (Mintz et al., 2001, 
Garcia-Garcia et al., 2011).  The final image created is a three-layer appearance of the 
coronary artery in alternating bright and dark echoes: a bright echo from the intima, a 
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dark zone from the media, and a bright echo from the adventitia (Gussenhoven et al., 
1989, Nishimura et al., 1990, Pandian et al., 1988) (Fig 1). For the usual IVUS 
transducers (20-40 MHz), the axial resolution is approximately 150-200µm and the 
lateral resolution is 200-250µm with >5mm depth penetration (Nissen and Yock, 2001).  
 
There are 2 different types of IVUS transducer: mechanical single element rotating 
transducer and the solid state electronic phased array transducer (Mintz et al., 2001, 
Garcia-Garcia et al., 2011, Nissen and Yock, 2001, McDaniel et al., 2011). The 
mechanical system utilizes a single rotating transducer, which is driven by a flexible 
drive cable at 1800 rotations per minute to sweep a beam almost perpendicular to the 
catheter. It offers a greater resolution owing to its higher frequency system and also a 
more uniform pullback. This system is available commercially as the 40 MHz iCross or 
Atlantis SR Pro catheters (Boston Scientific, Santa Clara, California), the Revolution 45 
MHz catheter (Volcano Corp, Rancho Cordova, California), and the 40 MHz Lipiscan 
IVUS (InfraReDx, Burlington, Massachusetts). The electronic phased array system on 
the other hand uses multiple transducer elements which are arranged in an annular array 
and sequentially activated to generate an image. Commercially, it is available as the 5F 
20MHz Eagle Eye catheter (Volcano Corp). Benefits of this system include enhanced 
trackability and lack of non-uniform rotational distortion artefacts. The latter is unique 
to mechanical system and is due to mechanical binding of the drive cable (ten Hoff et 
al., 1989). 
 
II. CLINICAL APPLICATION 
Evaluation of ambiguous lesions in non-left main coronary artery 
	 18 
   Assessment and management of angiographic intermediate lesions (50-70% stenosis) 
are a regular clinical dilemma faced by an interventional cardiologist. This issue is 
further compounded by various angiographic limiting aspects, such as lesion 
eccentricity, vessel overlapping and tortuosity, degree of calcification, and diffuse 
reference vessel disease (Sipahi et al., 2006). In this context, IVUS has the ability to 
provide complementary information to coronary angiogram with its excellent spatial 
orientation. In fact, the use of pre-intervention IVUS in coronary artery disease 
management has been reported to result in redirection of therapy in up to 40% of 
patients (Mintz et al., 1994).  
 
Although fractional flow reserve (FFR) is currently being preferred as the 
investigational tool to assess the functional significance of an intermediate lesion (Tobis 
et al., 2007, Kern and Samady, 2010, Kern et al., 2006), IVUS has an advantage in 
permitting precise quantification of anatomical distribution and morphology of a lesion; 
an important consideration in devising a procedural strategy and device selection prior 
to stenting. Several studies have also reported reasonable correlation between structural 
data derived from IVUS with physiological parameters from FFR (Abizaid et al., 1998, 
Nishioka et al., 1999, Abizaid et al., 1999, Koo et al., 2011, Kang et al., 2012, Ben-Dor 
et al., 2012). For example, earlier studies have identified IVUS derived minimum lumen 
area (MLA)<4mm2 as being haemodynamically significant when compared with FFR 
and SPECT imaging (Nishioka et al., 1999, Abizaid et al., 1998). Furthermore, using 
this MLA cut off, a long term follow up study reported a low event rate among patients 
who had their intervention deferred for an MLA³4mm2 (Abizaid et al., 1999). The latter 
studies however suggest a lower MLA cut off value of 2.4-3.6mm2 as being 
haemodynamically significant as compared with FFR (Koo et al., 2011, Kang et al., 
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2012, Ben-Dor et al., 2012). This apparent discrepancy is not entirely surprising given a 
single MLA value is significantly influenced by multiple factors including size of a 
vessel, lesion location and length, and the presence of plaque rupture (Kang et al., 
2012). Therefore, a combination of IVUS derived parameters, such as plaque burden, 
area stenosis, and lesion length also needs to be taken into consideration when assessing 
an intermediate lesion (McDaniel et al., 2011, Sipahi et al., 2006, Lee, 2012). 
Illustration of basic IVUS measurement can be seen in figure 2. 
 
Evaluation and management of left main coronary artery disease 
Evaluation of left main disease severity: It has been well documented that quantifying 
angiographic left main disease severity especially that which involves the proximal 
segment is particularly challenging, in part, due to measurements that have a significant 
interobserver variability (Fisher et al., 1982, Isner et al., 1981). This interobserver 
variability relates to three major anatomical factors which impair left main evaluation, 
which includes aortic cusp opacification, short length of vessel trunk, and the presence 
of bifurcation or trifurcation at the distal segment (Nissen and Yock, 2001). 
Furthermore, streaming in the aortic cusp can obscure the ostium of the left main, 
leaving the angiographers relying on contrast reflux and disengagement of the catheter 
to visualize the ostium. On the other hand, the short segment of the left main shaft 
leaves little reference site for comparison. Also, the bifurcation into sub-branches at the 
distal end potentially conceal the distal left main. IVUS, in contrast, suffers not from the 
aforementioned limitation making it an investigation of choice when assessing left main 
lesion (Fig 3).  
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In the case of evaluating an angiographic intermediate left main stenosis, an IVUS 
minimum lumen diameter (MLD) of <2.8mm or an MLA<6mm2 suggest a 
physiologically significant stenosis and thus merits revascularisation (Sipahi et al., 
2006, Tobis et al., 2007). A study of 55 patients with moderate left main disease 
demonstrated that these cut off values correlate well with physiologically significant 
lesion as assessed by FFR with a sensitivity of 93% and a specificity of 98% (Jasti et 
al., 2004). Additionally, a recent multicentre prospective study showed that deferral of 
revascularisation among patients with a left main MLA³6mm2 carried a similar 
outcome with the revascularised group who had a left main MLA<6mm2, during long 
term follow up (de la Torre Hernandez et al., 2011). Another comparative study used an 
MLA cut off value of 7.5mm2 to determine whether a patient should undergo 
revascularisation or to have a deferral strategy (Fassa et al., 2005). It concluded that 
during the mean follow up of 3.3 +/- 2 years, there was no difference in major adverse 
cardiac events (MACE) between the two cohorts. Altogether, in conjunction with 
clinical information, it is reasonably safe to defer revascularisation in patients with 
MLA³7.5mm2 and to consider revascularisation in patients with MLA<6mm2. Patients 
with intermediate MLA value (6-7.5mm2) would require further physiological 
assessment, for example with an FFR (Kern and Samady, 2010). Based on the available 
evidence, IVUS was given a class IIA indication for the assessment of angiographically 
indeterminant left main coronary artery disease by the recent joint American College of 
Cardiology/American Heart Association/Society for Cardiovascular Angiography and 
Interventions (ACC/AHA/SCAI) guideline (Levine et al., 2011).   
 
IVUS guided PCI for unprotected left main disease: Aside from its ability to provide 
further stratification of left main disease severity, IVUS also made a major contribution 
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in the area of unprotected left main PCI. Patients with significant left main disease 
(³50% stenosis) carry a high-risk mortality and morbidity from cardiovascular events 
considering the area of myocardium at risk should the flow in this vessel becomes 
compromised. To date, coronary artery bypass surgery (CABG) remains the “gold 
standard” treatment for majority of significant left main disease especially in those with 
multivessel involvement. Nevertheless, the introduction of drug eluting stent (DES) has 
ushered a new era of complex PCI, such as unprotected left main coronary artery 
disease and bifurcation lesion PCI due to its low rate of restenosis (Garg and Serruys, 
2010). The use of pre-intervention IVUS in left main PCI permits a detailed assessment 
of the vessel anatomy, the size of the vessel, and to determine the extent of ostial 
involvement at the daughter sub-branches (Tobis et al., 2007, Kang et al., 2011c). This 
information helps the operator to optimize stent selection and provide complete disease 
coverage. IVUS also assists in ensuring adequate stent expansion and apposition; 
important risk factors for restenosis and stent thrombosis (Sonoda et al., 2004, Sakurai 
et al., 2005, Palmerini et al., 2011). Finally, IVUS also reveals the extent of 
calcification. This information will be useful in deciding whether to employ a debulking 
strategy with rotational atherectomy to optimise stent placement (Park et al., 2001, 
Takagi et al., 2002, Anderson et al., 2002).  
 
The role of IVUS guided strategy for unprotected left main PCI however remains a 
controversial issue given the conflicting data in the literature (Palmerini et al., 2011). 
Nonetheless, several recent reports provide clinical data favouring its routine use. In a 
large Korean registry study (Park et al., 2009), the use of IVUS guided left main PCI 
was associated with a 3 year reduction in mortality when compared with angiographic 
guided PCI. This benefit is particularly observed among the 145 matched pairs of 
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patients who receive drug-eluting stents (4.7% vs. 16%, p= 0.048). Similar findings 
were demonstrated in Premier of Randomized Comparison of Bypass Surgery versus 
Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery 
Disease (PRECOMBAT) trial, which reported a low event rate in the PCI group and 
comparable outcome with the CABG group (8.7% vs. 6.7%, p=0.02 for non-inferiority) 
(Park et al., 2011). In this multicenter trial, IVUS was extensively used. Some of this 
clinical benefit may be derived from the effectiveness of IVUS in determining the 
extent of disease burden and lesion complexity thus assisting the operator with the 
appropriate procedural strategy. For instance, the MLA of the confluent zone between 
the distal segment of the left main coronary artery and its daughter branches has been 
shown to be an accurate indicator of bifurcation left main disease severity and a 
predictor of post stent underexpansion and clinical outcomes (Kang et al., 2011c, Kang 
et al., 2011b). Another study then demonstrated that among patients who undergo 
bifurcation left main PCI, those with post stenting underexpansion have significantly 
lower MACE free survival rates at 2 years when compared with the comparator group 
(Kang et al., 2011a). Acknowledging the above data, it would be reasonable to consider 
IVUS to guide all left main PCI.  
 
 
IVUS and PCI 
Refinement of PCI technique and practice: IVUS has been instrumental in helping us 
to understand the arterial responses to coronary intervention (Laskey et al., 1993, Mintz 
et al., 1992, Potkin et al., 1992, Suarez de Lezo et al., 1993) and has assisted in the 
improvement of technical details of the devices application and their manufacturing. For 
instance, IVUS has given a significant insight into the different mechanism of restenosis 
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post intervention. It has shown that whilst a combination of elastic recoil, concentric 
remodelling, and to a lesser role, local intimal hyperplasia, account for the mechanism 
of restenosis in post balloon angioplasty (Costa et al., 2001, Fuessl et al., 1999, Costa 
and Simon, 2005), neointimal hyperplasia is the sole mechanism of late lumen loss in 
the stented artery following bare metal stenting (Hoffmann et al., 1996, Mintz et al., 
1996). These observations were extremely valuable in guiding the development of 
management strategies for in stent restenosis. Furthermore, IVUS has also 
revolutionized the technique of stent deployment and guided us regarding post stent 
medication recommendations. Following the enthusiasm with the introduction of stents, 
clinicians began to notice issue with stent implantation in the form of subacute 
thrombosis (Orford et al., 2004). This issue was further compounded by major bleeding 
issues due to intensive use of oral anticoagulation. IVUS then began to identify the 
association between subacute stent thrombosis and stent deployment, such as 
inadequate stent expansion and incomplete stent apposition (ISA) (Nakamura et al., 
1994). Inadequate stent expansion occurs when part of the stent is insufficiently 
expanded when compared to the proximal and distal reference site. ISA, in contrast, 
refers to a lack of contact between the stent struts and the underlying arterial wall.  
Based on these observations, Colombo et al. recommended post stent deployment with 
high pressure balloon inflation to maximise stent apposition and expansion (Colombo et 
al., 1995). This strategy not only led to a reduction of stent thrombosis but also allowed 
oral anticoagulation to be replaced with dual antiplatelet therapy thus reducing the 
length of hospital stay and vascular complication rates.  
 
IVUS and bare metal stent (BMS) PCI: The benefit of IVUS in coronary intervention 
was initially demonstrated in the era of balloon angioplasty. Randomised and non-
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randomised IVUS trials demonstrated that an IVUS guided strategy resulted in 
improvement of final lumen diameter and caused significant reduction in clinically 
driven reintervention rates when compared with the angiography guided group (Stone et 
al., 1997, Frey et al., 2000). Yet, in Balloon Equivalent to STent (BEST) study which 
randomised 254 patients, the investigators reported a similar clinical outcome between 
IVUS guided balloon angioplasty (with provisional stenting) vs. routine angiography 
guided stenting (Schiele et al., 2003). It is worth noting that in this trial, there is a high 
crossover rate (44%) in the balloon angioplasty group to stenting. Taken together, the 
use of IVUS is effective in optimizing final balloon angiographic and clinical outcomes. 
This approach however was viewed as time consuming and cost ineffective especially 
as the stent profile continued to improve and its price continued to decline, leading to 
routine stenting becoming the preferred strategy for PCI (Orford et al., 2004).  
 
The benefit of IVUS guided strategy in BMS PCI has been examined in both 
observational (de Jaegere et al., 1998, Fitzgerald et al., 2000, Kasaoka et al., 1998) and 
randomised trials (Russo et al., 2009, Mudra et al., 2001, Oemrawsingh et al., 2003, 
Schiele et al., 1998). IVUS can be used to perform pre-interventional evaluation of the 
extent of lumen obstruction and the mechanism of obstruction (eg. thrombus or 
calcification). This in turn allows for each management strategy to be individualized 
and tailored according to patient’s clinical baseline status. Post intervention, IVUS may 
assist with optimizing procedural outcome, such as assessment of stent expansion and 
stent strut apposition, detection of PCI complication (eg. dissection, plaque shift), and 
identification of residual stenosis and stent fracture. Of these, inadequate stent 
expansion has been associated consistently with target vessel failure resulting from 
either in stent restenosis (Moussa et al., 1999, Hoffmann et al., 1998, de Feyter et al., 
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1999, Kasaoka et al., 1998) or stent thrombosis (Uren et al., 2002, Moussa et al., 1997). 
Despite its practical use and demonstrable benefit by case control studies, the data 
regarding IVUS clinical benefit from randomised trials are conflicting. The 
Thrombocyte activity evaluation and effects of Ultrasound guidance in Long 
Intracoronary stent Placement (TULIP) study, a randomised controlled trial involving 
144 patients with long disease segments (>20mm), demonstrated a significant 
improvement in both angiographic and clinical end points in the IVUS guided group 
when compared to the angiographic directed group (Oemrawsingh et al., 2003). Another 
trial, Angiography Versus Intravascular ultrasound-Directed stent placement (AVID), 
however reported a slight different outcome. AVID randomised 800 patients into IVUS 
vs. angiography guided intervention with total follow up of 12 months. Indeed, AVID is 
the largest randomised trial evaluating the benefit of IVUS in PCI using BMS. In this 
trial, an IVUS guided strategy resulted in the improvement of post procedural minimum 
stent area (a marker of adequate stent expansion) but did not result in the reduction of 
clinical end points (death/myocardial infarction/target lesion revascularisation) except 
in the subgroup with moderate size vessel (2.5-3.5mm) and in saphenous vein graft PCI 
(Russo et al., 2009). In this subgroup, the reduction in clinical end points were mainly 
driven by target lesion revascularisation. These findings were further replicated in a 
meta analysis from 7 randomised trials involving 2,193 patients (Parise et al., 2011). It 
concludes that IVUS guidance was associated with a significantly larger postprocedure 
angiographic minimum lumen diameter, lower rate of 6-month angiographic restenosis, 
a reduction in the revascularization rate, and overall MACE. However, no significant 
effect was seen for myocardial infarction or mortality. Overall, the efficacy of IVUS in 
optimizing procedural outcomes and reducing restenosis rates in BMS PCI is 
unquestionable, nonetheless its routine use in clinical practice still needs to be weighed 
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against a number of factors, including cost, time, availability, and the operators’ skill to 
accurately acquire and interpret the images.  
 
IVUS and DES PCI: The arrival of DES opened a new chapter in PCI. DES had been 
shown to significantly reduce the risk of restenosis to less than 10% (Abizaid et al., 
2004, Colombo et al., 2003, Serruys et al., 2002, Silber et al., 2009, Sonoda et al., 2004) 
when compared to BMS. It does this by inhibiting neointimal proliferation through its 
drug coating (Burke et al., 1999, Poon et al., 1996). As a result, operators began to put 
less attention on achieving optimal final procedural outcome as they would when 
inserting a BMS (Colombo et al., 1995). However, the discovery of increasing 
incidence of stent thrombosis, especially very late stent thrombosis in the patients 
receiving DES has resulted in renewed interest in the use of IVUS to direct therapy.  
 
Stent thrombosis, despite its rare occurrence (annual risk ~0.5%), carries significant 
morbidity and mortality rates (Serruys and Daemen, 2007). The overall prognosis is 
poor with 10-30% mortality rate. Several precipitating factors have been implicated to 
cause stent thrombosis and these essentially can be categorized as patient factors, lesion 
characteristics, device factors, and procedural factors. IVUS has provided significant 
insights into the morphologic pattern and possible causes of stent thrombosis following 
DES implantation, specifically stent underexpansion and ISA. Fuji et al conducted a 
retrospective analysis on 15 patients who developed stent thrombosis following 
successful DES implantation (Fujii et al., 2005). They reported that lesions leading to 
stent thrombosis had more stent underexpansion, smaller minimum stent area, and 
residual edge stenosis. The strong association between IVUS detected stent 
underexpansion and stent thrombosis was also observed and well established in various 
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other DES trials (Liu et al., 2009, Okabe et al., 2007, Alfonso et al., 2007, Takebayashi 
et al., 2005, Vautrin et al., 2012, Cheneau et al., 2003). The role of ISA in causing stent 
thrombosis, on the other hand, is still controversial. Firstly, ISA is common, occurring 
in 10-20% of DES cases and can be acute or late (Mintz, 2007a). Whilst acute ISA is 
largely procedural related, late ISA may be due to a combination of positive vessel 
remodelling (ie. vessel expansion), intimal hyperplasia, or dissolved thrombus which 
can lead to a gap between vessel wall and stent (Mintz, 2007b). Secondly, there remains 
uncertainty regarding the link between ISA and stent thrombosis. In a case control study 
by Cook et al, a significantly high rates of ISA were noted in the very late stent 
thrombosis patients as compared to the DES control group (Cook et al., 2007). This was 
also seen in another observational study (Siqueira et al., 2007) but not identified in 
follow up studies of large randomised DES trials (Jimenez-Quevedo et al., 2006, Ako et 
al., 2005, Kimura et al., 2006, Degertekin et al., 2003, Colombo et al., 2003). In a recent 
sub-analysis of a randomised DES trials, Cook et al reported that very late stent 
thrombosis and MACE occur more frequently in patients with ISA than without ISA 
(Cook et al., 2012). In this study, there was no difference in mortality.  
 
Based on these IVUS observations, several trials have been conducted to assess the 
clinical benefit of IVUS directed therapy in DES PCI. A study by Roy et al. compared 
1-year clinical outcomes in 884 patients who underwent IVUS-guided PCI with a 
propensity-matched cohort of angiographically guided patients (Roy et al., 2008). IVUS 
directed therapy was found to be associated with lower incidence of stent thrombosis at 
30 days (0.5% vs. 1.4%, p=0.05) and 1 year (0.7% vs. 2.0%, p=0.01) with no difference 
in the rates of myocardial infarction or death. Claessen et al. subsequently reported that 
an IVUS guided strategy resulted in a significant reduction of early, medium, and long 
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term clinical outcomes (Claessen et al., 2011), with this benefit largely driven by a 
reduction in myocardial infarction. In another large observational study involving 8,371 
patients, IVUS guided DES PCI was also found to be associated with a reduction in 
mortality rates at 3 years (HR 0.46; 95% CI 0.33– 0.66, P < 0.001) (Hur et al., 2011). 
Despite these observed benefits, to date there is still a lack of evidence regarding 
clinical benefits in randomised controlled IVUS studies. Indeed, there is only one 
randomised trial assessing the efficacy of IVUS use in DES implantation. Angiography 
Vs. IVUS Optimization (AVIO) trial randomised 284 patients with complex lesion (eg. 
small and diffuse vessel disease, bifurcation lesion, chronic total occlusion) into IVUS 
guided or angiography guided arms (Colombo, 2010). Optimal stent expansion was 
defined as achieving ³70% of the cross sectional area of the post dilation balloon. The 
results at 9 months follow up indicated that an IVUS guided strategy resulted in a larger 
post procedural minimum lumen diameter but no difference was observed in the rate of 
MACE. On balance, there is no current strong recommendation for routine use of IVUS 
to guide PCI. However, IVUS use should be considered in patients with high risk of 
stent thrombosis or in patients whereby the consequence of stent thrombosis is fatal, 
such as left main coronary artery disease. IVUS should also be considered for 




Despite its clinical advantages over coronary angiography, the widespread use of IVUS 
has been somewhat limited by its invasive nature. The safety of IVUS has been 
investigated extensively and has a low rate of complications (Hausmann et al., 1995, 
Batkoff and Linker, 1996, Bose et al., 2007). The most common complication recorded 
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is transient vessel spasm, which occurs in the order of 2% of procedures. Major IVUS 
complications, such as dissection and abrupt vessel closure are rare, occurring in <0.5% 
of procedures (Bose et al., 2007). Importantly, IVUS has not been shown to result in 
accelerating disease progression (Ramasubbu et al., 2003, Guedes et al., 2005). 
 
III. RESEARCH APPLICATION 
Evaluation of atherosclerotic plaque progression/regression  
Atheroma burden and its rate of progression, as measured by serial IVUS has been 
associated with increased risk of future cardiac events (von Birgelen et al., 2004, 
Nicholls et al., 2010). As a result, serial change in IVUS-measured atheroma burden has 
been used extensively in randomised clinical trials as a surrogate clinical end point to 
assess various novel (Tardif et al., 2004, Serruys et al., 2008, Nissen et al., 2008b, 
Nissen et al., 2007, Nissen et al., 2003, Nissen et al., 2006b) or existing cardiovascular 
medications (Nissen et al., 2006a, Nissen et al., 2008a, Nissen et al., 2004b, Nicholls et 
al., 2011, Nissen et al., 2004a, Nasu et al., 2009, Hirohata et al., 2010). The use of 
IVUS as a surrogate end point allows trials to be conducted in a shorter time frame with 
smaller number of participants; thus, it helps in expediting the process of drug 
development rather than progressing early to a costly Phase 3 trial, which may yield a 
negative result. Amongst these trials, IVUS has provided especially a significant insight 
into the impact of statin therapy on the natural history of atherosclerosis. The use of 
intensive statin therapy is not only shown to halt disease progression but may also 
results in disease regression (Nissen et al., 2006a, Nicholls et al., 2011). Furthermore, 
virtual histology-IVUS (VH-IVUS) has extended this observation by demonstrating that 
statin therapy also results in a change of plaque composition (Nasu et al., 2009, Nozue 
et al., 2012). Altogether, these trials demonstrate that pharmacological therapy has the 
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potentials to halt, reverse, and alter the course of the natural history of atheroma 
progression. 
 
The quest of accurately defining vulnerable plaque  
In the last decade, IVUS technology has been constantly used in the research arena in an 
attempt to identify vulnerable plaque, the major substrate for acute coronary syndrome 
(ACS). Vulnerable plaque or thin-capped fibroatheroma (TCFA) is defined 
histologically as a plaque with thin fibrous cap (<65µm), which is associated with a 
large necrotic core (often containing haemorrhage or calcification), reduced smooth 
muscle content, and a large number of infiltrative inflammatory cells, such as 
macrophages and activated T cells (Friedewald et al., 2008). Several other pathological 
features have also been observed to be present in TCFA, such as positive remodelling 
(expansion of the external elastic membrane in response to plaque accumulation) 
(Varnava et al., 2002) and abundant intraplaque vasa vasorum, indicating 
neoangiogenesis and active inflammation (Kolodgie et al., 2003, Galis and Lessner, 
2009). Some of these TCFA features like positive remodelling are easily identified by 
standard grayscale IVUS, however it falls short in its capability to characterize plaque 
composition. Grayscale IVUS is also limited due to its considerable postprocessing to 
produce an image and reliance on visual inspection of acoustic reflections to determine 
plaque component.  
 
In an effort to improve the detection of plaque composition, an IVUS capability called 
VH-IVUS was developed. VH-IVUS uses mathematical autoregressive spectral analysis 
of the radiofrequency backscatter data to generate a tissue map of 4 different plaque 
components: fibrous (green), fibrofatty (yellow green), necrotic core (red), and dense 
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calcium (white) (Nair et al., 2002) (Fig 4). An alternative algorithm to characterize 
plaque composition called integrated backscatter IVUS (IB-IVUS) has also been 
developed. This algorithm uses fast-Fourier transform analysis of the backscatter signal 
of a tissue volume to generate a tissue colour map (Kawasaki et al., 2002, Kawasaki et 
al., 2001). VH-IVUS’ accuracy in detecting these plaque types has been validated in 
vivo with a predictive accuracy of 87.1%, 87.1%, 88.3%, and 96.5% for fibrous, 
fibrofatty, necrotic core, and dense calcium respectively (Nasu et al., 2006). VH-IVUS 
however is limited in its ability to visualize thrombus and may misclassify it as fibrous 
or fibrofatty plaque. VH-IVUS derived TCFA (VH-TCFA) has been defined as 
confluent necrotic core rich plaque (>10%) without evidence of overlying fibrous tissue 
on 3 consecutive frames with the arc of the necrotic core in contact with the lumen for 
36 degrees along the lumen circumference (Garcia-Garcia et al., 2009). It must also 
have a percent atheroma of ³40% (Rodriguez-Granillo et al., 2005). Based on these 
criteria, investigators have found that VH-TCFA is more prevalent in the patients with 
ACS than in patients with chronic stable angina, inferring it as a reasonable surrogate 
for vulnerable plaque (Hong et al., 2007, Nakamura et al., 2009).  
 
Information derived from both IVUS and VH-IVUS has been evaluated as potential 
tools to individually risk predict focal atherosclerotic narrowings, as a possible better 
tool than traditional angiographic assessment. Yamagishi et al analysed 106 patients 
with angiographic minimal coronary artery disease with baseline conventional IVUS 
(Yamagishi et al., 2000). At follow up, plaques that resulted in ACS were found to 
exhibit higher baseline plaque volume, eccentric disease, and echolucent characteristics. 
Another landmark study which analysed the impact of baseline plaque composition on 
future coronary event is Providing Regional Observations to Study Predictors of Events 
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in the Coronary Tree (PROSPECT) trial (Stone et al., 2011). PROSPECT is the first 
prospective study utilising 3 separate imaging modalities: coronary angiogram, 
conventional greyscale IVUS, and VH-IVUS to assess the natural history of vulnerable 
plaque. In this study, 697 patients presenting with an ACS underwent 3 vessel IVUS 
and VH-IVUS imaging post PCI with the primary end point of MACE (death/cardiac 
arrest/myocardial infarction/rehospitalisation). After a median follow up of 3.4 years, 
20.4% of patients experienced a MACE event. Events were adjudicated to be related to 
culprit lesions in 12.9% of patients and to non-culprit lesions in 11.6%. Predictors for 
MACE in non-culprit lesion were identified to be diabetes, IVUS plaque burden of 
³70%, MLA £4mm2, and presence of VH-TCFA. In the absence of VH-TCFA, the 
event rate in the non-culprit lesions were reduced to 1.3-1.9% in 3 years depending on 
the presence of other risk factors. In another serial VH-IVUS study by Kubo et al, VH-
TCFA may stabilise, remain unchanged, or even evolve in a new territory suggesting 
that the natural history of vulnerable plaques is a dynamic process (Kubo et al., 2010). 
In summary, these new intravascular imaging modalities may provide incremental risk 
predictive information to standard measures of lesion specific vulnerability.  
 
Besides VH-IVUS, there are several other IVUS based technologies that have been 
developed as potential newer risk predictive tools. Some examples include IVUS 
elastography/palpography (Choi et al., 2007, Carlier et al., 2002, Suh et al., 2011) and 
contrast enhanced IVUS (CE-IVUS) (Vavuranakis et al., 2008, Vavuranakis et al., 
2007, Carlier et al., 2005). The former attempts to identify the plaque vulnerability by 
analysing the mechanical strain property of the arterial wall (Doyley et al., 2001). The 
differences in tissue deformity may allow differentiation of various plaque phenotypes. 
On the other hand, CE-IVUS uses a microbubble contrast agent in order to quantify 
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vasa vasorum density and plaque perfusion, which is a feature of inflammation, one of 
the major findings associated with vulnerable plaque (Carlier et al., 2005, Staub et al., 
2010). These technologies however remain unstudied concerning their ability to identify 
a high risk lesion subset that will lead to an adverse clinical event. 
 
IVUS has made a major leap in atherosclerosis imaging with the continual expansion of 
its new capabilities. In the near future, we will see a more IVUS synergism with other 
imaging modality to improve tissue characterization and arterial imaging. A co-
registration with optical coherence tomography (OCT), for example is already on the 
horizon (Li et al., 2010). The principle of OCT image acquisition is analogous to 
ultrasound imaging; however, a near infrared light source is used instead of sound to 
create an image. Its spatial resolution is 10 to 20 µm, which is approximately 10 times 
greater than that of IVUS and hence it provides an excellent contrast between lumen 
and vessel wall (Maehara et al., 2009). Owing to this, OCT is excellent in visualising 
the thin cap component of TCFA or stent strut coverage. It also has several other tissue 
characterization capabilities, such as red blood cell rich thrombus, platelet rich 
thrombus, and macrophages infiltration (Bezerra et al., 2009). With further evaluation, 
OCT, may lead future serial intravascular imaging studies looking at changes in these 
adverse findings located at the lumen-vessel wall interface when evaluating effects of 
novel new therapies.  
 
Use of IVUS in coronary endothelium vasodilator assessment  
Another exciting area from IVUS research is the use of IVUS to assess the relationship 
between segmental coronary endothelial function and regional plaque burden. It has 
been well established that endothelial dysfunction, as assessed by the vasodilator 
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responses to different endothelial dependent stimuli is associated with increased risk of 
future cardiovascular event (Halcox et al., 2002, Schachinger et al., 2000, Al Suwaidi et 
al., 2001). Recently, we published data from our sets of experiment that looked at the 
relationship between plaque burden and endothelial function as a plausible explanation 
for the association of this phenomenon with adverse clinical events (Puri et al., 2012a). 
Having considered the inherent limitation and image resolution of the traditional 
quantitative coronary angiogram (QCA), we utilized IVUS to evaluate the vasodilator 
properties of the study artery to the endothelial dependent stimulus, intracoronary 
salbutamol. The study showed a strong relationship between in vivo segmental human 
coronary endothelial dependent macrovascular and microvascular function with 
associated underlying atheroma burden. In addition, this coronary structure-function 
relationship seems to hold true irrespective of the nature of patient’s clinical 
presentation, indicating that the greater endothelial dysfunction observed in patients 
with ACS compared to stable angina was due to the underlying greater volume of 
atherosclerosis in ACS (Puri et al., 2013).  
 
The observations from these seminal works suggest that intravascular imaging modality 
with enhanced resolution and topographic capabilities may be of benefit when 
evaluating small, subtle changes in lumen size when assessing coronary vasodilator 
function. This concept leads to the first sets of experiments discussed in a separate 
chapter below which aims to assess the effectiveness of OCT in measuring changes in 
luminal area in response to vasoreactive stimulus. It was felt that the combination of 
OCT and IVUS would offer both superior luminal visualisation along with adequate 
depth penetration; therefore, the subtle relationship between segmental conduit 
vasoreactivity and regional atheroma volume with its composition may be readily 
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ascertained. This study, and our aforementioned works however, did not evaluate the 
impact of this dynamic process on the natural history of atheroscleroma progression 
over time. Furthermore, it did not investigate the impact of an endothelial independent 
stimulus, such as glyceryl trinitrate (GTN) and its association with regional plaque 
burden. These issues are a key focus of this thesis.  
 
Since the completion of these studies, further technological advances have been made in 
IVUS technology, particularly in relation to evaluating plaque composition. Recently, a 
combined catheter of IVUS and near infrared spectroscopy (NIRS) has been developed 
and performed in vivo (Schultz et al., 2010, Garg et al., 2010, Gardner et al., 2008, 
Waxman et al., 2009). NIRS provides information of atheroma composition by 
analysing the pattern of near infrared light absorbance by different tissue (Figure 5). It 
is superior to IVUS in terms of its ability to detect cholesterol lipid crystals, a major 
component of fibroatheroma’s necrotic core (Moreno et al., 2002); however, it does not 
provide any structural information. Several investigators have shown the association 
between NIRS positive lesions and acute coronary events (Madder et al., 2013, Madder 
et al., 2012); indeed, the finding of positive NIRS signal in a vessel may yield 
significant prognostic implication (Goldstein et al., 2011, Oemrawsingh et al., 2014). It 
will be the first time that NIRS imaging technology has been used to assess coronary 
endothelial function in a longitudinal imaging study, and we hope the result of these 
experiments will provide important new insight regarding the significance of human 
coronary structure function and its impact upon the natural history progression of 




The role of IVUS in the world of interventional cardiology continue to evolve in 
parallel with the refinement of PCI technique, devices, and approach. IVUS has played 
an important role in helping us to understand the different arterial response to various 
interventional approach as well as guiding the clinician with the device selection and 
strategy. Its role is even more paramount in the area of complex PCI, such as left main 
or bifurcation disease whereby the consequences of complication could be severe. 
Advances in IVUS, such as VH-IVUS and IVUS with NIRS capability also permit a 
more optimal characterization of atherosclerotic plaque. This provides not only a 
significant insight into the natural history of atherosclerosis but also an opportunity to 
evaluate the impact of different pharmacological therapy on modifying the disease 
progression. Furthermore, the utilisation of these imaging tools may be extended not 
only to evaluate fixed plaque composition, but also to evaluate dynamic function of the 
coronary arterial system. Finally, large prospective clinical trials are needed to assess 
the clinical benefit of emerging novel IVUS technology. 
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FIGURE 1: The three-layered appearance of a cross sectional coronary artery as 
assessed by IVUS.  
 





FIGURE 2: Basic IVUS measurement. 
A depicts the proximal reference segment. B is a cross sectional image taken from the 
most stenotic segment. C illustrates the calculation of the area stenosis and D 
demonstrates the IVUS quantification of plaque burden. Area stenosis is a measure of 
luminal stenosis relative to the normal reference segment. In contrast, plaque burden 
refers to the area within the EEM (external elastic membrane) which is occupied by 




FIGURE 3: Indeterminant ostial left main stenosis. 
This is the coronary angiogram picture taken from an 82 year old man who presents 
with chest pain and strongly positive stress test (left). Black arrow demonstrates area of 
haziness involving the ostium of the left main coronary artery. This segment correlates 
with the IVUS image on the right which shows an eccentric, calcified left main lesion, 
with minimum lumen area (MLA) of 3.9mm2. The patient was revascularised 










FIGURE 4: Lesion type classification by VH-IVUS. 
Based on the VH-IVUS algorithm, coronary lesion or plaque can be characterized 
according to the combination of different tissue colour map (fibrous=green; 
fibrofatty=yellow green; necrotic core=red; dense calcium=white). (A) Pathological 
intimal thickening. (B) VH-IVUS derived thin capped fibroatheroma. (C) Thick capped 
fibroatheroma. (D) Fibrotic plaque. (E) Fibrocalcific plaque. Reproduced with 







FIGURE 5: Near infrared spectroscopy output with the corresponding greyscale image 
(left). (Top right) Chemogram map of the artery wall indicating the location and 
intensity of lipid core plaque. (Middle right) Block chemogram displaying the presence 
of lipid core at 2mm segments in four probability categories (red<orange<tan<yellow). 
The lipid core burden index (LCBI) of the region of interest (subtended by the blue 













CHAPTER 2: CORONARY VASOACTIVE AGENT: 
PERIPROCEDURAL PHARMACOLOGY AND INVASIVE 
ASSESSMENT OF CORONARY ENDOTHELIAL FUNCTION 
Adapted from: Sidharta, S. and Puri, R. Coronary Vasoactive Agents: Periprocedural 
pharmacology, Global Textbook of Interventional Cardiology, 2016, S. Kapadia et al 
(in press). 
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Coronary vasoactive pharmacotherapeutic agents form an essential component of the 
interventional cardiologists armamentarium during diagnostic coronary angiography 
and percutaneous coronary intervention (PCI). Complications such as slow coronary 
flow or the ‘no-reflow’ phenomenon may arise during PCI as a result of several 
compounding mechanisms, including distal macro and micro-embolization, neutrophil 
plugging, vasoconstriction, myocyte contracture, local intracellular and interstitial 
oedema, intramural haemorrhage, and endothelial blistering (Niccoli et al., 2009, 
Kunadian et al., 2008). No-reflow is thought predominantly a microvascular disorder 
and therefore does not respond to mechanical intervention such as aspiration 
thrombectomy or coronary stenting, necessitating the administration of intracoronary 
(IC) vasoactive agents. IC vasoactive agents have also been utilized in a variety of 
clinical and research settings to evaluate the hemodynamic significance of angiographic 
indeterminate lesions, or during IC provocation for the evaluation of coronary 
vasospasm, microvascular dysfunction, and coronary endothelial function.  
 
This chapter aims to provide an overview of various IC vasoactive pharmacotherapeutic 
agents, including their clinical and research indications, mechanisms of action, and side 
effect profile. For the purpose of this discussion, we divide their site of action as either 
at the macrovascular level (epicardial), microvascular compartment, or both.  
 
Coronary Blood Flow Regulation. As in any vascular bed, myocardial blood flow 
depends upon the upstream coronary artery driving pressure and the resistance produced 
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by the downstream serial vascular compartments (Poiseuille’s Law). Owing to the fact 
that myocardial oxygen extraction from the coronary circulation is near maximal under 
basal conditions (up to 75% of arterial oxygen content), myocardial blood flow control 
is critical in safeguarding the homeostatic myocardial oxygen supply and demand 
relationship in preventing ischaemia or infarction (van de Hoef et al., 2012). Central to 
this role is the intricate network of coronary resistance vessels (Kern et al., 2006). 
Coronary arterial resistance is determined by the summed resistances of the entire 
epicardial coronary conductance (R1), pre-capillary arterioles (R2), and intramyocardial 
capillary resistance circuits (R3) (Kern and Lim, 2006).  
 
The epicardial coronary tree measures approximately 0.5–5mm in diameter and offers 
little resistance to coronary blood flow until atherosclerotic obstructions occurs (van de 
Hoef et al., 2012). These arteries are lined with vascular endothelium and smooth 
muscle cells which contract and relax in response to various circulating factors 
including vasoactive substances, neurohormonal stimuli, and flow mediated 
endothelium-dependent vasodilators or vasoconstrictors (Deussen et al., 2012). The 
dynamic nature of these interactions will be discussed in greater detail below. The 
principal control and regulation of coronary blood flow occurs at the level of coronary 
arterioles (100-500µm in diameter) and arterial microvessels (<100µm), collectively 
known as coronary microvessels (Marzilli et al., 2006). At this level, vascular tissue 
possesses intrinsic control mechanisms to maintain the homeostasis of the local 
microenvironment in the form of myogenic response to changes in intravascular 
pressure and flow induced dilation response to changes in shear longitudinal stress. 
Myogenic control is largely endothelium-independent and critical in modulating basal 
tone for maintenance of physiological intraluminal pressure, whilst flow mediated 
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dilation is largely endothelium-dependent (Marzilli et al., 2006). Altogether, coronary 
vascular resistance is a product of several inter-related mechanisms, including 
myocardial metabolism, autoregulation, myogenic control, neural control, and 
endothelial function.   
 
 
II. PREDOMINANTLY CORONARY MACROVASODILATORS 
Nitrates 
 
Nitric oxide (NO) is an endothelium-derived vasoactive substance which has critical 
function in mediating coronary vasodilation. This substance counters the effects of other 
endothelium-derived vasoconstrictors, such as thromboxane and endothelin (Davignon 
and Ganz, 2004). It also inhibits platelets activation (Andrews et al., 2001), leucocyte 
adhesion (Kubes et al., 1991), vascular smooth muscle cell proliferation (Garg and 
Hassid, 1989), and preventing oxidative modification of low-density lipoprotein 
cholesterol (LDL-C) (Rubbo et al., 2002). Nitric oxide is synthesized in a pulsatile 
manner within the endothelium from its precursor, L-arginine by the enzymatic action 
of nitric oxide synthase (NOS). Central to the regulation of NOS activity is the Ca2+-
activated calmodulin complex (Forstermann and Sessa, 2012). The rise in intracellular 
Ca2+ induces the binding of calmodulin to NOS which in turn activates NO synthesis. 
Cofactors such as flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), 
nicotinamide adenine dinucleotide phosphate (NADPH) and tetrahydrobiopterin (BH4) 
are also involved in the regulation of NO production (Forstermann and Sessa, 2012). 
Following synthesis, NO diffuses out into the adjacent vascular smooth muscle cells 
resulting in vasorelaxation by activating guanylate cyclase and subsequent increase in 
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the level of intracellular cyclic guanosine monophosphate (cGMP) (Davignon and 
Ganz, 2004) (Fig 1).  
 
Since the initial description of its clinical use by William Murrel in 1879 (Murrell, 
1879), nitrate remains a cornerstone therapy for stable angina pectoris and plays a 
significant role during invasive cardiovascular practice. Nitrate is an organic 
nitrovasodilator producing vascular relaxation by liberating NO within the vasculature. 
It is distinguishable from the inorganic nitrovasodilators, such as sodium nitroprusside, 
by its possession of a nitrate ester bond (R-O-nitric oxide2) (Anderson et al., 1994). 
Important similarities and differences exist in the biotransformation of these organic 
and inorganic nitrates, but it is generally accepted that they share a final common 
pathway via nitric oxide production. (For the purpose of discussion in this section, 
organic nitrate will be referred as nitrate. Inorganic nitrate such as sodium nitroprusside 
will be discussed in the separate section below).   
 
A number of studies have shown that nitrates dose-dependently dilate both normal and 
atherosclerotic epicardial coronary arteries, while producing only a submaximal, brief 
effect on coronary flow. Feldman and colleague (Feldman et al., 1979) demonstrated 
that intracoronary nitrates can increase epicardial coronary artery diameter by 10-30%. 
Brown et al. (Brown et al., 1984) furthermore reported that about 70% of coronary 
lesions, from mild to severe, dilate measurably in response to nitroglycerin largely as a 
result of dilation of the normal portion of the artery within the eccentric stenosis. 
Nitrates, however has minimal or no effect on coronary microvessels. In an experiment 
using porcine coronary arteries, Sellke and colleagues (Sellke et al., 1990) demonstrated 
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that vessels >200µm in diameter were very responsive to nitrates, whereas those 
<100µm in diameter dilated only minimally. This finding was supported by Kurz et al. 
(Kurz et al., 1991) in their in vivo coronary microvessel model. One plausible 
explanation for this phenomenon is due to the inability of the smaller coronary 
microvessels to convert nitroglycerin to its active vasodilator intermediate (Harrison 
and Bates, 1993). Taken together, nitrates predominantly dilate large epicardial 
coronary arteries and arterioles >100µm in diameter with little or no effect at the 
coronary microvascular level. Moreover, given its site of action on the vascular smooth 
muscle cells, nitrates likewise has the capacity to dilate the venous system (Rosen et al., 
1987) and collateral vessels (Feldman et al., 1981). Indeed, several studies 
demonstrated a greater sensitivity of nitrates for veins than arteries (Rosen et al., 1987, 
Stiefel and Kreye, 1984, Toyoda et al., 1986). The outcome of this increased venous 
capacitance is a decrease in preload which then leads to reduction in ventricular volume 
and ultimately oxygen consumption.  
 
Due to its effects, nitrates are widely used in the catheterization lab to reduce or reverse 
coronary vasospasm as a primary observation, or secondary to catheter placement, 
ballooning, or stenting a vessel. Furthermore, nitrates are frequently used during 
invasive endothelial function research protocols when assessing endothelium-
independent vasodilator function (Flammer et al., 2012). A dose ranging from 50-400 
microgram (mcg) is typically used depending on the clinical circumstances and 
patient’s tolerance. Its main side effect is hypotension and headache secondary to 
vasodilation of the venous system and the cerebral vasculature (Bagdy et al., 2010). 
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III. PREDOMINANTLY CORONARY MICROVASODILATORS 
Adenosine 
Adenosine is an endogenous purine nucleoside. It is produced from dephosporylation of 
extracellular adenosine 5’-triphosphate (ATP) released from the parenchymal tissue 
(including endothelium) by the enzymatic action of ecto-5′-nucleotidase (Mustafa et al., 
2009). It functions as a cytoprotective modulator under both physiological and 
pathological conditions. This protective response might take the form of increased 
blood supply (vasodilation or angiogenesis), ischaemic preconditioning (in the heart, 
brain, or skeletal muscle), and/or suppression of inflammation (activation and 
infiltration of inflammatory cells, production of cytokines and free radicals) (Jacobson, 
2009). Although originally identified within the myocardium in 1929 (Drury and Szent-
Gyorgyi, 1929), it took another 60 years to uncover its effect within the human coronary 
circulation (Wilson et al., 1990). Adenosine is a potent arteriolar vasodilator and 
mediates vasodilation largely via an endothelium-independent and partly, endothelium-
dependent manner (Dinckal et al., 2003, Duffy et al., 1999, Smits et al., 1995, Jones et 
al., 1995). Currently, there are four known adenosine receptor (AR) subtypes, namely 
A1, A2A, A2B, and A3 receptors (Mustafa et al., 2009). Although all four AR subtypes 
are found within coronary smooth muscle cells, only the A2AAR and A2BAR have been 
identified on coronary endothelial cells (Olanrewaju et al., 2000, Olanrewaju et al., 
2002). Among these receptors, A2AAR plays a significant role in controlling coronary 
vasodilation, while other receptors play a lesser role (Frobert et al., 2006, Hodgson et 
al., 2007, Morrison et al., 2002, Talukder et al., 2003). The binding of adenosine on 
A2AAR activates adenylate cyclase and results in accumulation of cyclic adenosine 
monophosphate (cAMP) and subsequent opening of intermediate calcium-activated 
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potassium channels (Mustafa et al., 2009). The end result is hyperpolarization of 
smooth muscle and vasorelaxation. Adenosine has a differential effect on resistance 
coronary vascular beds, chiefly dilating vessels with diameter <100µm. Larger 
resistance vessels or epicardial conduit coronary arteries dilate via a NO-dependent 
mechanism from the concomitant increase in local shear stress (flow-mediated dilation). 
Adenosine has an extremely short half-life (<10 seconds) due to both its high affinity 
red blood cell uptake and rapid inactivation by adenosine deaminase. Several 
medications, such as ticagrelor and dipyridamole have been shown to increase the level 
of adenosine plasma concentration by inhibiting the red blood cells reuptake of 
adenosine in both healthy volunteers (Biaggioni et al., 1986, Conradson et al., 1987, 
Wittfeldt et al., 2013) and acute coronary syndrome (ACS) patients (Bonello et al., 
2014). Therefore, in patients receiving ticagrelor or dipyridamole, a reduction of 
adenosine dose is suggested to prevent supernormal response to adenosine used for both 
therapeutic and diagnostic applications (Voci and Pizzuto, 2014). 
 
Indication: (1) Hemodynamic evaluation of coronary stenosis. The use of fractional 
flow reserve (FFR), the ratio of maximal blood flow in a stenotic artery to normal 
maximal flow (Pijls et al., 1996), allows physicians to determine whether an 
angiographic lesion is functionally significant. FFR-guided PCI has been demonstrated 
to result in superior clinical outcomes compared with angiographic-guided PCI (Bech et 
al., 2001, Pijls et al., 2007, Tonino et al., 2009, Pijls et al., 2010). Indeed, in a large-
scale randomized controlled trial, FFR-guided PCI coupled with optimal medical 
therapy was associated with significant reductions in the composite endpoint of death, 
myocardial infarction, and urgent revascularization when compared with optimal 
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medical therapy alone (De Bruyne et al., 2012). This benefit seems to be preserved in 
the ACS population as well (Sels et al., 2011). An FFR value of £ 0.8 is considered to 
be a functionally significant value (Tonino et al., 2009, De Bruyne et al., 2012).  
 
Valid FFR measurements are obtained following achievement of maximal coronary 
hyperaemia. Adenosine has been used extensively in various FFR studies due to its 
ability to achieve maximal reduction in coronary microvascular resistance, its brief 
duration of action, and minimal toxicity profile. Intravenous adenosine with doses 
ranging between 140-170 mcg/kg/min are considered “gold standard” and have been 
shown to be safe and effective in achieving steady-state coronary hyperaemia (Kern et 
al., 2006). Consequently, intravenous adenosine permits clinicians to analyse the 
functional significance of segmental epicardial disease, including the evaluation of 
tandem stenosis during pressure wire pullback (Kim et al., 2012a, Pijls et al., 2000). 
Limitations associated with the use of intravenous adenosine include longer preparation 
time, higher cost, the need for central vein cannulation (or at minimum a large bore 
antecubital vein access), and higher occurrence of systemic side effects (eg. flushing, 
angina-like chest pain, transient bradyarrhythmia (sinus bradycardia, 2:1 AV block, 
asystole, and hypotension). An IC bolus dosing of adenosine, on the other hand, is 
simple, inexpensive, and relatively free of systemic side effects, thus making it an 
attractive option, especially when transradial coronary angiography approach was used 
and femoral access has not been prepared. The use of IC adenosine also presents 
different challenges, notably, in obtaining steady response of maximal hyperaemia. 
Indeed, a failure to produce maximal hyperaemia has been reported to occur in 10-15% 
cases following IC adenosine (Jeremias et al., 2000). To circumvent this issue, it is 
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recommended that serial incremental IC adenosine doses should be given until a plateau 
of response is achieved. Recent data have demonstrated that higher dose of adenosine 
(300-720 mcg) increased the sensitivity of FFR for the detection of haemodynamically 
significant coronary stenosis (De Luca et al., 2011, Lopez-Palop et al., 2013). Taken 
together, adenosine is generally safe and effective in achieving maximal hyperaemia in 
the recommended intracoronary and intravenous dosages. 
 
(2) Managing No reflow. The ultimate goal of reperfusion therapy, either via a 
thrombolytic agent or PCI, is to achieve optimal vessel patency and re-establishment of 
coronary flow. A number of reports however have shown that up to 40% of patients fail 
to achieve adequate myocardial tissue perfusion (defined as Thrombolysis in 
Myocardial Infarction (TIMI) flow grade >2) despite patent coronary artery and absence 
of coronary dissection or vasospasm; a phenomenon known as ‘no reflow’ (Piana et al., 
1994, Kondo et al., 1998, Iwakura et al., 1996). No-reflow is associated with adverse 
clinical outcomes and is caused by microvascular obstruction, arising from multiple 
pathophysiological mechanisms such as distal embolization of plaque and/or thrombus, 
intracellular oedema and endothelial damage, in situ thrombosis, microvascular spasm, 
activation of the inflammatory cascade with leucocyte stasis and extravasation, and 
finally reperfusion injury (Niccoli et al., 2009, Jaffe et al., 2010).  
 
The data from various animal models of reperfusion injury have consistently 
demonstrated the efficacy of adenosine in reducing infarct size, improving left 
ventricular function, and improving coronary blood flow (Olafsson et al., 1987, Velasco 
et al., 1991, Babbitt et al., 1989). Likewise, in a number of prospective observational 
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studies involving acute myocardial infarction patients who undergo primary 
angioplasty, the use of both IC and IV adenosine were found to be well tolerated and 
associated with smaller infarct size and reductions of the no reflow phenomenon 
(Garratt et al., 1998, Marzilli et al., 2000, Assali et al., 2000, Claeys et al., 2004). 
However, randomized controlled trials have yielded somewhat conflicting results. In the 
Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial (Mahaffey et al., 
1999), a total of 236 ST elevation myocardial infarction (STEMI) patients receiving 
thrombolysis were randomized into 3-hour IV adenosine infusions (70 mcg/kg/min) or 
placebo. A significant 33% relative reduction in infarct size was noted in the adenosine 
group compared with placebo. This trial nonetheless was not powered for clinical 
endpoints. AMISTAD-II was subsequently designed to address this clinical question in 
much larger patient population (n = 2118) (Ross et al., 2005). However, the trial failed 
to show the benefit of IV adenosine in reducing adverse clinical events (death, 
congestive heart failure, rehospitalization), although the study medication was well 
tolerated and resulted in a dose-related reduction in infarct size. Lastly, in a meta-
analysis of trials investigating the impact of adenosine on angiographic and clinical 
outcomes of ACS patients undergoing PCI or thrombolysis for STEMI, Navarese and 
colleague found that the use of adenosine was associated with a significant reduction of 
post-procedural no-reflow (OR [95% CI] = 0.25 [0.08–0.73], p = 0.01), even though 
this failed to translate into clinical benefits in the long term (Navarese et al., 2012). It is 
possible that the lack of clinical benefit noted in these studies was due to small sample 
size or suboptimal study design. Taken together, adenosine appears to reduce the 
incidence of no reflow periprocedurally in the setting of primary PCI. Nevertheless, the 
clinical significance of these findings remains unclear. For the management of no 
reflow, we recommend IC adenosine, initially at low dose e.g. 30 mcg bolus, with 
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escalating doses of 60, 90, 120 injected every 20–30 seconds, as AV conduction allows 
is considered by many as an effective first option (Wong et al., 2013). 
 
Papaverine 
Originally discovered by Georg Merck in 1848 (Merck, 1848), papaverine is an opiate 
derivative with smooth muscle relaxing properties. It exerts its smooth muscle relaxing 
action by inhibiting cyclic nucleotide phosphodiesterase, resulting in an increase of 
cAMP and smooth muscle relaxation (Boswell-Smith et al., 2006). Papaverine is a 
potent, direct coronary microvascular dilator with nominal effects in epicardial 
conduits. Historically, it has been the agent of choice for evaluating coronary flow 
reserve (Carlson et al., 1988, Christensen et al., 1991, Wilson and White, 1986). IC 
papaverine administration has been shown to increase coronary blood flow velocity up 
to four to five times above baseline in patients with normal epicardial coronary arteries 
(Wilson and White, 1986). Its half-life is approximately 2 minutes with peak effect after 
administration at 10–30 sec and the duration of plateau is around 45–60 sec, four times 
longer than that of IC adenosine (Zijlstra et al., 1986). Understandably, this makes 
papaverine an attractive vasoactive agent for FFR evaluation especially in the setting of 
diffuse disease due to its ability to achieve maximal and steady hyperaemia. IC 
papaverine of 10-20mg produces a similar complete, true steady-state hyperaemic 
response compared with 140mcg/kg/min of IV adenosine (De Bruyne et al., 2003), or 
0.56-0.84mg/kg of IV dipyridamole (Wilson and White, 1986). Its use during FFR 
evaluation however has been superseded by adenosine due to its side effect profile and 
thus akin to nitroprusside, its use should be reserved for patients with contraindications 
to adenosine. Papaverine may induce significant electrocardiographic changes such as 
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ST-segment depression or QT interval prolongation, and polymorphic ventricular 
tachycardia and fibrillation (Talman et al., 1990, Wilson and White, 1988, Kern et al., 
1990). Also, it has been shown to generate myocardial lactate production irrespective of 
the degree of coronary flow reserve and electrocardiographic changes in patients with 
normal coronary arteries (Takeuchi et al., 1996). Lastly, as a potent coronary 
microvascular dilator, papaverine may improve TIMI flow in some cases of no reflow 
(Ishihara et al., 1996, Wilson et al., 1989). However due to lack of prospective, 
randomized data and its side effect profile, it is currently not recommended for use 
outside of a research setting.  
 
IV. MIXED CORONARY VASODILATORS 
Sodium Nitroprusside 
Sodium nitroprusside is a direct NO donor with fast release kinetics and potent 
vasorelaxant effects on conduit vessel, arterial resistance, and venous capacitance 
vessels. It has a preferential vasodilatory action on coronary arterioles without affecting 
myocardial contractility or other types of smooth muscle. Its vascular smooth muscle 
relaxing effects are analogous to the actions of nitrates (via NO-cyclic GMP pathway). 
Nitroprusside was first described by Hermann (Hermann, 1886) in 1886, however its 
potential clinical utility was not unravelled until 1928 when Johnson (Johnson, 1928) 
described its therapeutic effect in reducing hypertension by peripheral vascular 
relaxation independent of the autonomic innervation (Tuzel, 1974). Since then, 
nitroprusside has been widely used, particularly in the intensive care setting, for treating 
hypertensive crises or severe left ventricular failure. 
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Indication: Like adenosine, nitroprusside has been evaluated as an adjunctive 
pharmacotherapeutic option to PCI for improving coronary flow in the setting of acute 
myocardial infarction or other high risk PCI situations, such as saphenous vein graft 
intervention. Whilst observational studies demonstrated improvement in the degree of 
microvascular dysfunction following nitroprusside when assessed with both 
angiographically (TIMI flow or corrected TIMI frame count) (Hillegass et al., 2001, 
Airoldi et al., 2007, Pasceri et al., 2005, Wang et al., 2004) and via microvascular 
resistance indices (Morimoto et al., 2012), randomized trial data have been inconsistent. 
Hendler and colleagues (Hendler et al., 2006) randomized 40 patients undergoing 
primary PCI into 3 investigational groups of IC nitroprusside, IC adenosine, and IC 
verapamil (with IC nitroglycerin as the control). Nitroprusside was associated with 
greater myocardial blush scores, correlating with a significant improvement in LVEF 
when compared with adenosine and verapamil. Subsequent randomized studies by Amit 
and colleagues (Amit et al., 2006), as well as the large multicenter Randomized 
Evaluation Of Intracoronary Nitroprusside vs Adenosine After Thrombus-aspiration 
During Primary PErcutaneous Coronary Intervention for the Prevention of No Reflow 
in Acute Myocardial Infarction (REOPEN-AMI) trial (Niccoli et al., 2013) on the other 
hand failed to demonstrate improvement of microvascular obstruction and no reflow 
with IC nitroprusside. It seems likely that the discordance between these findings is 
possibly due to underpowering differential dosing regimens and potential elements of 
selection and measurement bias. In terms of the dosage for managing no reflow, a 100 
mcg to a total of 1mg bolus is recommended and can be administered via the coronary 
guide catheter. Common side effects include hypotension, headache, and nausea. 
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With increasing clinical use of FFR, there is also growing interest in finding an 
alternative agent to adenosine which is inexpensive yet as effective as adenosine in 
achieving maximal hyperaemia. Parham et al (Parham et al., 2004) compared the 
hyperaemic and haemodynamic responses of IC nitroprusside with IC adenosine (30-50 
mcg bolus) in 21 patients undergoing cardiac catheterization with angiographically 
normal left anterior descending arteries. Using a Doppler wire, time to peak and average 
peak velocity were similar between nitroprusside and adenosine with the 3 doses of IC 
nitroprusside that were administered (0.3, 0.6, and 0.9 mcg/kg). The duration of 
coronary hyperaemia was ~25% greater with IC nitroprusside in comparison with IC 
adenosine. FFR measurements with IC nitroprusside were identical to those obtained 
with IC adenosine (r = 0.97). As an extension to this work, Leone and colleagues 
(Leone et al., 2012) evaluated correlations of FFR readings using IC nitroprusside (0.6 
mcg/kg), incremental doses of IC adenosine (60, 300, and 600 mcg), and IV adenosine 
(140 mcg/kg/min). The IC adenosine dose used in this study was higher than the dose 
used by Parham et al. (Parham et al., 2004). Both IC adenosine doses and nitroprusside 
induced significant decreases of FFR compared with baseline levels (p <0.001), 
however the mean FFR with nitroprusside was significantly higher compared with IV 
adenosine. Nevertheless, higher doses of IC nitroprusside (100 mcg) have been reported 
to correlate well with that of IV adenosine (Rudzinski et al., 2013). This suggests that 
IC nitroprusside is safe and effective for the induction of maximal coronary 
hyperaemia. However, given its limited body of evidence, it is currently difficult to 
advocate its use during routine clinical practice except perhaps in the setting whereby 
adenosine is absolutely contraindicated such as drug hypersensitivity or severe chronic 




Verapamil is a non-dihydropyridine calcium channel blocker which acts on the voltage 
operating “slow Ca++ channels” located on the vascular smooth muscle cell and 
myocardium during depolarization, thereby producing relaxation of coronary vascular 
smooth muscle and subsequent coronary vasodilation (Durand et al., 1991, Nayler and 
Krikler, 1974). Since its introduction in 1962 as an antiarrhythmic and coronary 
vasodilator (Haas, 1964), verapamil has been used widely as an effective anti-angina 
and antihypertensive agent. In contrast to nitrates which dilate epicardial conduits in a 
flow-independent manner, verapamil mediates epicardial vasodilation in flow-
independent as well as a flow-dependent manner, making this vasoactive agent both a 
macro- and microvascular dilator, although its action upon resistance coronary arterioles 
seems to predominate (Oldenburg et al., 2000, Adachi et al., 1987, Messing et al., 
1991). Using a coronary Doppler guide wire in the left anterior descending artery, 
Ishihara et al. (Ishihara et al., 1997) demonstrated that verapamil caused a dose-
dependent increase in coronary blood flow velocity and decrease in coronary vascular 
resistance index, confirming its vasodilating effects on coronary resistance vessels.  
 
Indication: Early animal experiments demonstrated that timely administration of 
verapamil was associated with reduction in the index of myocardial ischaemic injury 
and increased contractile function of the post-ischaemic stunned myocardium following 
myocardial infarction (Campbell et al., 1986, Reimer and Jennings, 1984, Przyklenk 
and Kloner, 1988). Plausible mechanisms to account for these beneficial verapamil 
effects include reduction in global oxygen demand (Taniyama et al., 1997), inhibition of 
platelet aggregation and thus thrombus formation (Ikeda et al., 1981), and coronary 
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microvascular vasodilatation (Messing et al., 1991). Intuitively, verapamil would be a 
useful vasoactive agent in the setting of no reflow and indeed its efficacy in improving 
myocardial perfusion or decreasing the incidence of no reflow has been documented in 
a number of observational trials of infarct PCI (Piana et al., 1994, Pomerantz et al., 
1991, Werner et al., 2002, Rezkalla et al., 2010), degenerated vein graft PCI (Kaplan et 
al., 1996), and rotational atherectomy (Nunez et al., 1996). Similar observations were 
noted in various randomized trials. In a trial involving 40 patients with acute myocardial 
infarction who underwent primary PCI, Taniyama and colleague (Taniyama et al., 
1997) observed that IC administration of 0.5mg verapamil followed by oral 
administration significantly reduced the myocardial contrast echocardiographic derived 
low reflow zone, a measure of improved microvascular function, by 25% (p <0.05), 
compared with placebo. Other angiographic or contrast echo-derived indices of 
coronary microvascular function also improved with verapamil compared with placebo. 
Furthermore, a recent meta analysis (Su et al., 2013) reported that in the setting of PCI 
for ACS, verapamil was associated with decreased incidence of no-reflow, a decreased 
corrected thrombolysis in myocardial infarction (TIMI) frame count (CTFC), 
improvement in the TIMI myocardial perfusion grade, and a reduced incidence of major 
adverse cardiac events (MACE) during hospitalization and 2 months following PCI. 
Although the benefit of verapamil on no reflow seems compelling, its impact on clinical 
outcome appears modest due to small number of patients and short-term follow-up 
available in these randomized trials. Finally, IC verapamil should also be considered in 
the setting of acute episodes of vasospastic angina refractory to nitrate therapy (Babbitt 
et al., 1988). A dose of 100 µg up to 1 mg administered via IC route is recommended 
for the management of no reflow with careful attention to be paid on verapamil’s side 
effects which include hypotension, bradycardia, and transient heart block.  
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V. NOVEL AGENT 
Nicorandil 
Nicorandil is a vasoactive agent with two modes of function. It activates ATP-sensitive 
K+ channels and also possess a nitrate group in its chemical structure. Whilst its 
potassium channel opening effect induces hyperpolarization of the vascular smooth 
muscle cell membrane resulting in vasodilation of peripheral and coronary resistance 
arterioles, its nitrate-like activity also produces vasodilation of the systemic veins and 
epicardial conduit vessels (Suryapranata, 1993). The precise mechanism of nicorandil-
mediated vasodilation has not been fully elucidated but does not appear to involve 
cholinergic, adrenergic, histaminergic, or adenosine-potentiating mechanisms 
(Suryapranata, 1993). IC nicorandil produces a dose-dependent increase in coronary 
blood flow velocity and associated coronary hyperaemic response, comparable to that of 
IC papaverine (Hongo et al., 1995) and IV adenosine (Jang et al., 2013). Its peak effect 
occurs at 17-20 seconds following administration with plateau duration of 25-27 
seconds (Hongo et al., 1995). Furthermore, when administered via IC route, nicorandil 
also produced fewer changes in blood pressure, heart rate and PR interval, less chest 
pain, and no atrioventricular block when compared with other vasoactive agent such as 
papaverine or adenosine (Jang et al., 2013).  
 
Indication: Nicorandil has been shown to improve a number of surrogate endpoints in 
the setting of acute myocardial infarction (Miyazawa et al., 2006, Ota et al., 2006, Ito et 
al., 1999), vasospastic angina (Lablanche et al., 1993), and complex PCI with rotational 
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atheretectomy (Tsubokawa et al., 2002). In a recent meta analysis involving 1680 
infarct PCI patients, Wu et al. found nicorandil to significantly reduce the incidence of 
TIMI flow grade scores ≤2, reduce the TFC, increase left ventricular ejection fraction 
(LVEF), along with reducing the incidence of ventricular arrhythmia and congestive 
heart failure (Wu et al., 2013). It is worth noting however that the largest randomized 
trial included in this meta-analysis, the Japan-Working Groups of Acute Myocardial 
Infarction for the Reduction of Necrotic Damage by Atrial Natriuretic Peptide or 
Nicorandil (J-WIND) study reported no difference in the primary end point of total 
infarct size (estimated by creatine kinase) and LVEF between nicorandil and control 
(Kitakaze et al., 2007). Several mechanisms have been postulated to explain the unique, 
cardioprotective effects of nicorandil, including a reduction in preload and afterload, 
anti-free radical and neutrophil modulating properties (Pieper and Gross, 1992, Yasu et 
al., 2002), vasodilatation of small coronary arteries, and beneficial effects on ischaemic 
preconditioning (Matsubara et al., 2000). Many of these effects, particularly the latter 
are likely mediated via its KATP channel opening effects (Genda et al., 2002). The 
efficacy of nicorandil in the setting of elective PCI nonetheless is modest (Hwang et al., 
2013, Kim et al., 2012b) except in cases when rotational atherectomy is considered. 
Matsuo and colleagues (Matsuo et al., 2007) randomized 200 patients undergoing 
rotational atherectomy to an IC nicorandil versus verapamil infusions. Compared with 
verapamil, nicorandil was associated with a significantly lower incidence of no 
reflow/slow flow, persistent ST-segment elevation and myocardial infarction with no 
differences in rates of restenosis and MACE at 6 month follow up. Taken together, 
nicorandil provides an additional and interesting therapeutic option in the 
catheterization lab and its use could complement the aforementioned vasoactive agents.  
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VI. SPASM TESTING AGENT 
Ergonovine 
Vasospastic (variant or Prinzmetal) angina is a clinical syndrome characterized by rest 
angina, typically with onset between midnight and early morning, and associated with 
transient ST segment changes on electrocardiogram (Maseri and Chierchia, 1982). A 
positive diagnostic ECG changes encompass an ST elevation of 0.1 mV or more, an ST 
depression of 0.1mV or more, or new appearance of negative U waves recorded in at 
least two contiguous leads on the 12-lead ECG during an episode (Group, 2010). 
Episodes are caused by focal or diffuse epicardial coronary spasm and typically occur in 
patients with minor coronary artery stenosis. Multiple factors have been postulated that 
contribute to the pathogenesis of coronary spasm including endothelial dysfunction, 
vascular smooth muscle hypersensitivity and increased autonomic tone, oxidative stress 
and genetic disorders (Shimokawa, 2000). Prognosis of patients with variant angina is 
relatively benign with more than 80% of patients experiencing myocardial infarction 
free survival at 10 years follow up (Yasue et al., 1988, Ong et al., 2011). Nonetheless, 
coronary vasospasms can lead to ACS and arrhythmias, including ventricular 
arrhythmias and sudden cardiac arrest (Togashi et al., 2013, Ong et al., 2008). 
Diagnosis of variant angina can be extremely challenging due to the elusive nature of 
the disease. The gold standard investigation is a catheterisation lab based coronary 
provocation test. Although numerous agents have been described, in clinical practice, 
ergonovine and acetylcholine are the 2 agent most commonly used. 
 
Ergonovine is a naturally occurring argot alkaloid which produces direct 
vasoconstriction by activation of serotonergic (5-HT2) receptors located on the vascular 
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smooth muscle (Suyama and Kuriyama, 1984). Ergonovine is predominantly 
metabolized by the liver and serves as a major substrate of CYP3A4 hepatic enzymes. 
The use of ergonovine as a provocative agent in the setting of coronary disease was first 
described by Stein to diagnose evidence of “coronary insufficiency” (Stein, 1949, Stein 
and Weinstein, 1950). Since then, a growing body of literature has demonstrated the 
utility and safety of ergonovine as a diagnostic tool for variant angina (Curry et al., 
1979, Curry et al., 1977, Heupler et al., 1978, Schroeder et al., 1977). A positive 
ergonovine test is defined as transient occlusion (>90% stenosis) of a coronary artery 
accompanied by signs and symptoms of ischaemia, such as angina and ST-segment 
changes on coronary angiography, at 1-2 minutes following its IV or IC administration 
(Group, 2010). Ergonovine commonly causes a generalized or diffuse reductions of 
epicardial lumen diameters of the order of 15% to 30% on angiography and therefore in 
isolation, this is not representative of variant angina (Conti et al., 1979, Chahine, 1980). 
The key value of the administration of ergonovine is that, in selective patients, namely 
those with true variant angina, focal spasm can be elicited with the full spectrum of its 
signs and symptoms. If the patient develops mild, diffuse coronary artery constriction, 
the test is considered negative; if severe, focal spasm develops, with associated 
diagnostic ECG changes, the test is interpreted as positive. Prior to performing the test, 
a washout period of 1-2 days or longer is required for any calcium channel blockers and 
nitrate therapy.  
 
Both IC and IV ergonovine have been shown to be sensitive and specific in diagnosing 
coronary vasospasm (Sueda et al., 2003, Sueda et al., 2004, Waters et al., 1983, Hackett 
et al., 1987). Nevertheless, IV ergonovine may present some drawback such as 
induction of perpetuating multivessel spasm and haemodynamic instability, making 
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angiographic acquisition challenging (Hackett et al., 1987). Also, it does not permit 
individual provocation of left and right coronary artery as with IC administration. For 
this reason, the Japanese Cardiac Society Guidelines recommend an IC administration 
of ergonovine with an incremental dose of 20-60 mcg (slow injection over 2-5 minutes) 
into the left coronary artery then right coronary artery with 5 minutes apart between 
each administration (Group, 2010). The safety of IC ergonovine was recently evaluated 
in a multicenter trial involving 1244 patients with vasospastic angina (Takagi et al., 
2013). Takagi and colleague reported that the use of IC ergonovine has an acceptable 
safety profile with low incidence of arrhythmia (1.6% ventricular ectopic beats, 0.8% 
VT/VF, 0.6% AV block, and 0.4% bradycardia/sinus pause) (Takagi et al., 2013). Other 
adverse reactions to ergonovine include ischaemia, myocardial infarction, nausea, and 
abdominal cramps (Chahine, 1980). 
 
Acetylcholine 
Acetylcholine is a muscarinic cholinergic agonist which mediate coronary vasodilation 
via an endothelium-dependent mechanism. Early animal experiments using canine 
(Feigl, 1969, Vanhoutte and Cohen, 1984) and simian (Toda, 1983) models 
demonstrated the IC administration of acetylcholine to produce both epicardial and 
resistance coronary artery vasodilation. The pioneering work by Furchgott and 
Zawadzki (Furchgott and Zawadzki, 1980) showed that acetylcholine causes 
vasodilation by inducing the vascular endothelium to release endothelium-derived 
relaxing factor, subsequently identified as NO, which then diffuses out into the vascular 
smooth muscle to produce relaxation via a cGMP dependent pathways (Furchgott and 
Vanhoutte, 1989). This observation was further extended in human by Ludmer and 
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colleagues (Ludmer et al., 1986) using quantitative coronary angiography (QCA) to 
evaluate the change in conduit artery diameter in response to graded infusion of 
acetylcholine. The use of acetylcholine in the catheterization laboratory at this stage is 
mainly limited as a provocative agent for the evaluation of variant angina or research 
protocol-driven evaluation of coronary endothelial function. 
 
The administration of IC acetylcholine as a provocative agent for variant angina testing 
was first described by Yasue and colleagues (Yasue et al., 1986). They conducted a 
study involving 28 patients with a clinical diagnosis of variant angina on the basis of 
typical angina pain associated with transient electrocardiographic ST elevation. These 
investigators reported that IC acetylcholine at doses of 10-50 mcg in the right coronary 
artery and 10-80 mcg in the left coronary artery produced focal spasm in 94% of the 
coronary arteries suspected to be the culprits for the patients’ symptoms. Similar 
findings of acetylcholine as a reliable and effective provocative agent for evaluating 
coronary vasospasm were also reported by subsequent investigators (Miwa et al., 1991, 
Okumura et al., 1988a, Sueda et al., 2002). IC acetylcholine is known to have high 
sensitivity (90%) and specificity (99%) for the diagnosis of variant angina (Okumura et 
al., 1988b). It has a shorter half-life yet similar potency when compared with 
ergonovine (Sueda et al., 2003, Sueda et al., 2004). Data from Sueda and coworkers 
showed that residual effects of acetylcholine are not observed within 10 minutes 
following injection (Sueda et al., 2003). Compared with ergonovine, IC acetylcholine 
also caused more diffuse and distal spasms, whereas IC ergonovine is thought to have a 
more ‘focal’ effect; indicating that ergonovine may provoke more vasoreactivity (Sueda 
et al., 2003). A careful and judicious approach is crucial when employing IC 
acetylcholine as some major side effects, such as sustained ventricular tachycardia / 
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fibrillation, shock, bradyarrhythmia (atrioventricular block, bradycardia, or sinus pause) 
– especially with right coronary injection have been reported (Sueda et al., 2000). The 
event rate for these arrhythmic complications however is low (<5%) (Takagi et al., 
2013, Ong et al., 2014). A dose of 20, 50, and 100mcg for left coronary artery and 20 
and 50 mcg for the right coronary artery injected over 20 seconds is recommended with 
at least a 5-minute interval between boluses (Group, 2010). An insertion of a temporary 
wire is also suggested for an additional haemodynamic support. 
 
VII. CORONARY ENDOTHELIAL FUNCTION ASSESSMENT  
The endothelium plays a critical role in maintaining the vascular homeostasis by 
secreting a wide range of factors which regulate vascular tone, cellular adhesion, 
thrombus formation, smooth muscle cell proliferation, and vessel wall inflammation 
(Farouque and Meredith, 2001). Altered endothelial function (endothelial dysfunction), 
largely evaluated by vasodilator responses to endothelium- dependent stimuli occurs in 
the setting of established atherosclerosis, hypertension, smoking, dyslipidaemia, 
systemic inflammation, and diabetes mellitus (Davignon and Ganz, 2004). Importantly, 
endothelial dysfunction, measured in the peripheral (Gokce et al., 2003) or coronary 
circulations (Halcox et al., 2002, Schachinger et al., 2000, Suwaidi et al., 2000) has 
been shown to be associated with a greater risk of future MACE, independent of the 
traditional cardiovascular risk factors. Altogether, this leads to a well-regarded 
hypothesis that coronary endothelial dysfunction plays a significant role in triggering 
the event of atherogenesis and may contribute to the atherosclerosis associated 
ischaemic sequelae.  
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Coronary endothelial function assessment involves pharmacological or physiological 
stimulation of endothelial release of NO and other vasoactive compounds. These 
vasodilator responses are then compared to the corresponding responses to 
endothelium-independent stimuli (eg. nitroglycerin) to demonstrate the integrity of 
vascular smooth muscle. Some of the pharmacological agents which have been used to 
assess endothelium dependent coronary vasomotor effects include acetylcholine 
(Ludmer et al., 1986), salbutamol (Barbato et al., 2005), serotonin (McFadden et al., 
1991), substance P (Quyyumi et al., 1997), and bradykinin (Aptecar et al., 2000). To 
date, acetylcholine remains the “gold standard” vasoactive agent for the invasive 
evaluation of coronary endothelial function (Flammer et al., 2012).  
 
The basic methodology for coronary endothelial function assessment is now well 
established in coronary research laboratories (Flammer et al., 2012). Typically, during 
standard invasive coronary endothelial function assessment, QCA or intravascular 
ultrasound (IVUS) is used, and changes in conduit vessel diameters and cross-sectional 
areas in response to graded concentration of endothelium-dependent stimuli are 
documented. In addition, the integrity of coronary microvascular function is evaluated 
simultaneously by measuring the changes in coronary blood flow using a flexible and 
steerable 0.014-inch diameter Doppler guidewire. Coronary blood flow is measured as a 
product of Doppler-derived average peak velocity and the cross sectional area of the 
vessel obtained by angiography or IVUS (Doucette et al., 1992). In coronary vessels or 
segments with preserved endothelial function, the normal response is vasodilation and 
increase coronary blood flow. In the setting of endothelial dysfunction however, NO 
production is insufficient and/or outweighed by the production of endothelium-derived 
vasoconstrictors, such as endothelin, and hence endothelium-dependent vasoactive 
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agent administration results in paradoxical vasoconstriction due to its direct effect on 
the vascular smooth muscle (Ludmer et al., 1986).  
 
Endothelial adrenergic system 
Adrenergic stimulation plays a key role in the regulation of coronary vasomotor tone 
and requires a complex interaction between receptors acting as vasoconstrictors (a-
adrenergic) and receptors acting as vasodilators (b-adrenergic) (Barbato, 2009). 
Presently, three b-adrenergic receptors subtypes have been identified within the human 
coronary circulation: b1, b2, and b3-subtypes (Hodgson et al., 1989a, Sun et al., 2002, 
Dessy et al., 2004). Data from ex vivo and in vivo human studies demonstrated greater 
(up to 5-fold) densities of b-adrenergic receptors within arteriolar resistance coronary 
vessels when compared with small to medium sized arteries and significantly more 
when compared with proximal epicardial vessels (up to 34-fold) (Ferro et al., 1995, 
Amenta et al., 1991, Barbato, 2009, Barbato et al., 2003).  Among these receptor 
subtypes, b1 receptors are predominantly located within the epicardial coronary arteries 
whereas b2 and b3 receptors are present at the level of coronary microvessels. 
Interestingly, in a morphology characterization study of adrenergic receptors within 
human epicardial arteries, Jensen and coworkers found that two thirds of all adrenergic 
receptors are of the b adrenoreceptor type, with 99% of these being the b2-subtype 
(Jensen et al., 2009). Whether these receptors are fully functional nonetheless remains 
to be elucidated. Both b1 and b2 are characteristically expressed on endothelial and 
vascular smooth muscle cells, whereas b3 adrenoreceptors are mainly expressed on the 
vascular endothelium. A number of studies have demonstrated that b2 adrenergic 
receptors mediated coronary vasodilation via endothelium-dependent pathways, either 
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by inducing NO release or activation of K+ channel induced hyperpolarization (Ferro et 
al., 2004, Grossini et al., 2009, Jayachandran et al., 2001, Barbato et al., 2005, Puri et 
al., 2012a, Wilkinson et al., 2002). A number of investigators have shown that this 
process can be altered in the setting of atherosclerosis, such that vasodilation can be 
typically blunted or even paradoxical vasoconstriction can occur (Barbato et al., 2005, 
Puri et al., 2012a, Wilkinson et al., 2002, Puri et al., 2013).  
 
Salbutamol is a short-acting, direct b2 agonist which has been used to treat asthma since 
1969 (Choo-Kang et al., 1969, Palmer and Diament, 1969). Its administration into the 
human coronary circulation with incremental doses of 0.125 mcg up to 5 mcg/min 
produces increase in left ventricular contractility yet without significant changes in the 
systemic blood pressure, left ventricular end-diastolic pressure, and heart rate (Newton 
et al., 1999). In their seminal work, Wilkinson and colleagues demonstrated the 
potential use of salbutamol as a vasoreactive agent for endothelial function assessment 
(Wilkinson et al., 2002). Using pulse wave analysis for non-invasively assessing 
peripheral endothelial function, they showed that inhaled salbutamol induced increase 
in forearm blood flow and this response was blunted with the NO inhibitor, N -
monomethyl-L-arginine (L-NMMA), indicative of its NO-dependent properties. This 
observation was validated in the human coronary microcirculation by Barbato et al. 
(Barbato et al., 2005) and within both the micro-and epicardial circulations by Puri et al. 
(Puri et al., 2012a). In unobstructed coronary arteries, even in the setting of non-ST-
segment elevation myocardial infarction, IC salbutamol appears safe with low rate of 
coronary spasm (0.06%) and no arrhythmia documented (Barbato et al., 2005, Puri et 
al., 2012a). These findings are important for a number of reasons. Firstly, although 
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endothelial dysfunction has been demonstrated to be an independent predictor of 
cardiovascular events, its use is impractical and limited due to its invasive nature. 
Secondly, the “gold standard” provocative agent, acetylcholine, potentially causes a 
number of significant adverse effects, such as major coronary vasospasm and 
bradyarrhythmia thus limiting its use for non-invasive evaluation. Salbutamol on the 
other hand is an effective but gentler vasomotor provocative agent with no arrhythmic 
complications. Its inhaled delivery also permits for non-invasive endothelial function 
evaluation and therefore possible for use in clinical and larger-scale settings. Its wider 
application however still awaits further observational and interventional studies in a 
much larger population spanning longer duration of follow up. 
 
VIII. CONCLUSIONS 
Coronary blood flow regulation is complex and is a function of the dynamic interplay 
between perfusion pressure, conduit obstruction, and resistance vessels. These 
interactions can be modulated for diagnostic and therapeutic purposes with various 
coronary vasoactive agents. Their use has been pivotal in the cardiac catheterization lab 
as an aid to diagnostic coronary angiography for diagnosing haemodynamically 
significant stenosis or coronary vasospasm, as well as an important therapeutic adjunct 
to PCI for improving myocardial perfusion and ultimately the clinical outcome. 
Understanding the role, mechanisms, and side effects of these medications are crucial to 
ensure safe and appropriate administration to optimize the clinical evaluation and 
treatment of the wide-spectrum of coronary arterial disease.  
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FIGURE 1. Mechanism of nitric oxide (NO) synthesis by endothelial cells. 
Stimulation of endothelial NO synthase in response to various stimuli leads to 
increased nitric oxide (NO) production in endothelial cells by receptor and non-
receptor and calcium-dependent and non-calcium-dependent pathways. NO then 
diffuses to vascular smooth muscle and causes relaxation by cGMP dependent 






TABLE 1. Summary of coronary vasoactive agents 




Dosage Side effects 







Purine nucleoside Resistance FFR:  
60 mcg LCA;  
40 mcg RCA  
(IC);  
­ 30-60mcg up  
to 150mcg  







If antecubital  
vein is used,  




Start with  
30mcg (IC)  
then  
­every 30mcg  
every 20 sec  







Nitroprusside Nitric oxide donor Mixed No reflow: 
100 mcg then 
titrate up to 
























Verapamil Calcium channel 
blocker 
Mixed No reflow: 
100 mcg up to 
1 mg (IC) 
 
Hypotension,  
Nicorandil K+ channel 
opener and NO 
donor 
Mixed No reflow: 
500 mcg to a 
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Backgrounds: Optical Coherence Tomography (OCT) is a catheter based intravascular 
imaging modality which provides a very high resolution image of vessel wall. In 
acquiring OCT images, angiographic contrast media is injected via an injection pump 
(total of 14mls, over 4 seconds, 300psi) to achieve effective intracoronary clearance of 
blood for optimal image acquisition. The influence of dye load and subsequent luminal 
measurements may vary at differing macro and microvascular conditions. 
Aims: To investigate the impact of luminal dimensions and differing microvascular 
resistance on human coronary artery luminal measurements acquired by OCT. 
Method: A total of 10 patients underwent serial imaging with intravascular ultrasound 
(IVUS) at baseline (used as a ‘gold standard’ comparator), followed by OCT. The OCT 
measurements were acquired during incremental intracoronary infusions of salbutamol 
as a proven microvascular vasodilator. Each IVUS and OCT runs were matched and 
analysed as 4 mm segments. To evaluate the impact of differing microvascular 
resistance and lumen dimension on OCT lumen measurement, we dichotomised the 
groups into small and large lumen groups divided around the IVUS segmental lumen 
volume (SLV) median.  
Results: A total of 49 matched segments were available for analysis. The mean SLV of 
all segments with IVUS was 79.29 ± 4.78mm3 compared with corresponding mean SLV 
of all segments with OCT, 73.52 ± 4.56mm3. OCT measurements in the small lumen 
group increased in response to incremental salbutamol dose (baseline 49.22 [30.76-
69.15] mm3, 0.3mcg salbutamol 62.47 [38.40-72.35] mm3, 0.6 mcg salbutamol 64.35 
[43.85-68.56] mm3, p = 0.0077) however this response was not observed in the large 
lumen group (baseline 102.6 [78.83-115.1] mm3, 0.3mcg salbutamol 89.28 [83.39-
103.3] mm3, 0.6mcg salbutamol 90.88 [81.36-107.2] mm3, p = 0.205). 
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Conclusion: Volumetric lumen assessment with OCT is increased by 25% in small 
vessels in the setting of a reduction in microvascular resistance. In the presence of 
significant epicardial coronary stenosis, this finding may have implications on the 
effectiveness of OCT to guide stent sizing. 
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INTRODUCTION 
Fourier-Domain Optical Coherence Tomography (FD-OCT) is a catheter based 
intracoronary imaging modality that provides high-resolution images using near-
infrared interferometry principle (Muller et al., 2010). The spatial resolution of OCT is 
10 to 20 µm, which is approximately 10 times greater than that of intravascular 
ultrasound (IVUS) and hence it provides an excellent contrast between the lumen and 
vessel wall. FD-OCT also provides a high frame rate and rapid pullback speed, thus 
enabling fast scanning of long coronary segments. Some of its applications include the 
identification of thin cap fibroatheroma (TCFA) (Kubo et al., 2007), thrombus imaging 
(Kume et al., 2006), and increasingly used to guide percutaneous coronary intervention 
(PCI) (Gomez-Lara et al., 2011).  
 
Coronary endothelial/vasodilator dysfunction is thought to play a mechanistic role in 
mediating coronary atheroma plaque disruption (Bogaty et al., 1994) which may 
eventually lead to adverse coronary events (Halcox et al., 2002, Schachinger et al., 
2000). Our group has recently shown, using IVUS imaging, that this vasodilator 
function is associated with plaque burden (Puri et al., 2012a). In light of a greater spatial 
resolution associated with OCT, future research in this area may gain benefit using this 
newer imaging modality. 
 
Despite emerging as a potentially attractive imaging modality for the assessment of 
epicardial coronary endothelial/vasodilator function, several technical aspects from 
OCT image acquisition need to be considered. Growing reports have documented 
significant discrepancy in the lumen evaluation between OCT and IVUS whereby IVUS 
derived lumen measurement tends to be larger than OCT, particularly in the smaller 
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epicardial coronary vessels (Okamura et al., 2011, Bezerra et al., 2013). Furthermore, 
during OCT image acquisition, angiographic contrast media is injected via an infusion 
pump to achieve effective intracoronary (IC) clearance of blood for optimal image 
acquisition. It could be speculated that this bolus injection may increase the arterial wall 
shear stress and hence impact upon the coronary vasodynamic assessment. FD-OCT 
lumen measurement analysis also has a potential to vary at differing macro and micro 
vascular conditions (Guagliumi et al., 2013). We aim to investigate the impact of lumen 
dimensions and differing microvascular resistance (in response to IC salbutamol 
provocation) on human coronary artery luminal measurements acquired by OCT, 
comparing this with baseline IVUS and OCT acquired measurements. Particularly, we 




Following informed consent, 10 consecutive patients who underwent elective coronary 
angiogram at the Royal Adelaide Hospital catheterization laboratories were enrolled. 
The target artery of interest must be “smooth” or have minimal disease, defined as 
<30% visual angiographic stenosis and not undergone previous PCI. All vasoactive 
medications were held 24 hours prior to the study. Patients with recent acute coronary 
syndrome, renal failure, cardiac failure, severe valvular heart disease, and prior 
coronary revascularization were excluded. This study was approved by the Royal 
Adelaide Hospital Research Ethics Committee. 
 
Intravascular imaging protocols. 
Coronary angiography was performed using standard 6 French technique. Intravenous 
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heparin (70 IU/kg) was administered for the research protocol. Each study participant 
underwent serial intravascular imaging with initial IVUS (40 MHz Atlantis® SR Pro 
catheter, Boston Scientific, Natick, MA, USA) run with automated pullback speed of 
0.5mm/s (used as a ‘gold standard’ comparator) and followed by serial FD-OCT (2.7-F 
C7 Dragonfly Imaging Catheter, LightLab Inc., Westford, Massachusetts) interrogation. 
Prior to FD-OCT catheter pullback, angiographic contrast media was injected through 
the guiding catheter via an injection pump (settings: 14 mL volume contrast, 4mL/s, 
300 psi per OCT run) to achieve effective IC clearance of blood for optimal image 
acquisition. All IVUS and FD-OCT acquisition were performed without glyceryl 
trinitrate (GTN) pre-treatment of the target artery. All the images were saved and 
recorded on a DVD for off-line analysis.  
 
During FD-OCT acquisition, serial 5-minute IC infusions via the guiding catheter at 2 
mL/min was administered: 5% dextrose, followed by 0.3 mcg/min and then 0.6 
mcg/min of salbutamol as the vasoactive agent. These doses are known to increase 
coronary blood flow by approximately 60% (Puri et al., 2012a, Barbato et al., 2005). At 
3 minute into each IC infusion, we recorded the patient’s haemodynamics (blood 
pressure and heart rate) followed by FD-OCT pullback at an automated pullback speed 
of 20 mm/s. The infusion was then continued for the remainder 2 minutes whilst FD-
OCT acquisition was undertaken. Each pullback recorded 54 mm of coronary artery 
over a 2-3 second period. Prior to the commencement of imaging, the Z-offset was 
adjusted for appropriate image calibration for accurate image measurements offline.  
 
Image analysis 
All IVUS and FD-OCT data was analysed using echoPlaque 3.0.60 (Indec Systems, 
	 85 
Santa Clara, CA, USA). For each run, the common most distal and proximal fiduciary 
markers (anatomical side-branches) were identified from corresponding IVUS and OCT 
pullbacks in order to define the region of vessel to be analysed. For IVUS imaging, 
cross-sectional images were selected every 30 frames (0.5 mm) apart. Coronary lumen 
and the external elastic membrane were traced by manual planimetry upon each selected 
IVUS frame, to enable the calculation of lumen area and plaque burden within each 
segment. Plaque burden was calculated as percent atheroma volume (PAV) within each 
segment (Nissen et al., 2004b). Briefly, the leading edges of the lumen and EEM were 
traced. Plaque area was defined as the area occupied between these leading edges. The 
PAV within each coronary segment was calculated as the proportion of the entire vessel 
cross-sectional area (of the respective coronary segment) occupied by atherosclerotic 
plaque. For OCT imaging, cross-sectional images were selected every 2nd frame (0.4 
mm) apart. Each IVUS and OCT run was precisely divided into pre-defined consecutive 
4 mm segments, comprising of 9 cross-sectional IVUS frames (with 8 x 0.5 mm 
intervals) and 11 cross-sectional OCT frames (with 10 x 0.4 mm intervals). Each 
segment was therefore analysed separately. The segmental lumen volume (SLV) was 
calculated as the average of lumen area within that particular segment and normalized 
as previously reported (Puri et al., 2012a). Using MIB software (Indec Medical 
Systems, Santa Clara, CA, USA), the corresponding IVUS and OCT pullbacks (with 
numbered frames) were simultaneously played in order to accurately frame match 
anatomical fiduciary markers between each run (Fig 1). This technique ensured that 
precisely the same arterial segments were consistently analysed between each IVUS and 
OCT run per patient. Only cross sectional images deemed acceptable for complete 
lumen tracing (frames that contained a complete lumen circumference) were included.  
 
	 86 
To evaluate the effects of different microvascular resistance on FD-OCT measurements, 
coronary segments were dichotomized as larger and smaller segments divided around 
the median IVUS-derived SLV. Furthermore, we dichotomized the coronary segments 




Sample characteristics are summarized as counts and percentages, means with standard 
deviation, or median with interquartile range as appropriate. Comparisons between SLV 
measured by IVUS versus OCT was conducted using paired Student t test. Group 
comparisons between serial OCT were performed with repeated measures one-way 
ANOVA. Log transformations were applied where appropriate. Statistical analysis was 




Baseline demographics are shown in table 1. The average age of our cohort was 60 
years and 70% were male. A total of 49 epicardial segments were analysed out of 10 
coronary arteries. The mean IVUS-derived SLV of all segments at baseline was 79.29 ± 
4.78 mm3, compared with a corresponding mean FD-OCT-derived SLV of 73.52 ± 4.56 
mm3 (p<0.0001), representing a relative difference of 7.3%.  
 
Microvascular resistance and FD-OCT measurement: impact of lumen size 
The mean FD-OCT derived SLV of all coronary segments at baseline, 0.3 mcg, and 0.6 
mcg salbutamol were 74.15 ± 31.92 mm3, 75.68 ± 26.79 mm3, and 74.35 ± 25.74 mm3 
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respectively (p = 0.55). FD-OCT measurements in the smaller IVUS-derived SLV 
group increased in response to IC salbutamol infusion at both the 0.3 and 0.6 mcg/min 
(baseline 49.22 mm3 [30.76-69.15]; 0.3mcg/min salbutamol 62.47 mm3 [38.40-72.35]; 
0.6 mcg/min salbutamol 64.35 mm3 [43.85-68.56], p = 0.0077) however this 
vasodilatory response was not observed in the larger IVUS-derived SLV group 
(baseline 102.6 mm3 [78.83-115.1]; 0.3mcg/min salbutamol 89.28 mm3 [83.39-103.3]; 
0.6mcg/min salbutamol 90.88 mm3 [81.36-107.2], p = 0.205) (Fig 2).  
 
Microvascular resistance and FD-OCT measurement: impact of plaque burden 
Coronary segments were also divided around the mean IVUS-derived segmental plaque 
burden (PAV) into low PAV group (mean: 22.39 ± 4.29 mm3) and high PAV group 
(mean: 45.43 ± 9.71 mm3) to determine the impact of plaque burden on epicardial 
vasomotor response as measured with FD-OCT. There was no significant difference in 
the vasodilatory response observed either in the low plaque volume group (dextrose: 
91.41 ± 28.05 mm3, 0.3 mcg salbutamol: 89.04 ± 23.82 mm3, and 0.6 mcg salbutamol 
85.88 ± 24.59 mm3; p = 0.088) or in the high plaque volume group (dextrose: 61.18 ± 
28.76 mm3, 0.3 mcg salbutamol: 66.47 ± 25.10 mm3, and 0.6 mcg salbutamol: 66.4 ± 
23.77 mm3; p = 0.16).   
 
DISCUSSION 
This is the first human in vivo study evaluating the impact of lumen size, plaque burden, 
and differing microvascular resistance state on FD-OCT coronary lumen measurement. 
We demonstrated that volumetric lumen assessment with FD-OCT is significantly 
increased in response to the microvascular vasodilator salbutamol in small vessels, 
while no change is observed in larger vessels. This finding was not seen under different 
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plaque burden conditions. Consistent with the previous reports (Okamura et al., 2011, 
Puri et al., 2012b, Kubo et al., 2013), at baseline, we found that coronary lumen 
dimension measured with IVUS was 7.3% larger when compared with FD-OCT. A few 
possible explanations may be provided to explain this measurement disparity, including: 
(1) sharper lumen-intima interface delineation by FD-OCT, resulting in more precise 
lumen visualization than IVUS; (2) faster FD-OCT pullback creating smoother 
longitudinal view; and (3) discrepancy in image gating between the two imaging 
modality (Bezerra et al., 2013). In spite of these suggestions, whether this discrepancy 
is due to FD-OCT underestimation or IVUS overestimation remains uncertain.  
 
We then explored the impact of various microvascular resistance condition on FD-OCT 
luminal measurements. Although there was no significant difference in the vasomotor 
response in the entire coronary segments following salbutamol injection, on further 
exploratory analysis, we noted an incremental epicardial vasodilatory response by 25% 
to increasing doses of IC salbutamol in small lumen segments which was not observed 
in the large lumen segments. Salbutamol, a beta 2 adrenoreceptor (AR) agonist, is a 
novel vasoreactive agent which is known to increase coronary blood flow by 50-60% 
via nitric oxide dependent pathway (Barbato et al., 2005, Puri et al., 2012a). It is 
generally thought that salbutamol exerts its conduit vasodilating property by reducing 
the coronary microvascular resistance, which in turn produces a shear stress dependent 
vasodilation (Barbato, 2009). Of note, vascular wall shear stress is indirectly 
proportional to the arterial radius (Davies, 2009). The impact of contrast injection 
during FD-OCT derived vasoreactive assessment needs to be mentioned as well. Even 
though at standard conditions the impact of this contrast injection may be minimal, it 
has been reported that contrast media may induce conduit vasodilation through various 
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mechanisms (Limbruno et al., 2000, Baile et al., 1999). We also speculate, with such an 
injection rate, it would be possible to generate a higher shear rate. Mechanistically 
therefore, this difference in luminal response likely relates to the greater increase in 
shear stress observed in smaller vessel, particularly in the setting of an increase 
coronary blood flow associated with a reduction in microvascular resistance. Given that 
reduction in lumen size and microvascular resistance occurs with significant epicardial 
coronary stenosis (Chamuleau et al., 2003), it is possible that these findings could have 
implications on stent sizing. 
 
The discrepancy in FD-OCT derived vasodilatory response in small versus large lumen 
was not seen in segments with different IVUS derived plaque volume. In our previous 
coronary endothelial function studies using IVUS, we were able to characterize 
systematically the segmental coronary structure-function relationship between atheroma 
plaque burden and epicardial coronary vasoreactivity (Puri et al., 2012a). We therefore 
hypothesized that the combined use of FD-OCT and IVUS, which leverage on both near 
field and far field resolution would provide an excellent imaging platform to conduct a 
‘gold standard’ coronary structure-function in vivo evaluation. The negative result of the 
current study however is important in highlighting the limitation of FD-OCT in 
coronary vasoreactive assessment. The injection of bolus contrast medium prior to 
image acquisition and its aforementioned impact on lumen measurement would make 
any dose response experiment challenging. Furthermore, characterization of the relative 
expression of alpha and beta AR subtypes within the human epicardial coronary arteries 
has uncovered that two-thirds of all such AR’s are of the beta-AR type, of which 99% 
are of the beta 2-AR sub-type (Jensen et al., 2009). Hence, the rapid contrast flush with 
FD-OCT acquisition may provide inadequate time for salbutamol to interact with its 
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corresponding epicardial receptor to generate adequate vasoreactive response, which in 
turn restrict the capacity to evaluate the underlying relationship between regional plaque 
burden and segmental coronary vasomotion. Lastly, the trade-off of the superior lateral 
resolution of FD-OCT is poor depth penetration, which limit its ability to assess 
atheroma volume. Hence, it may not be feasible to use FD-OCT as a standalone 
imaging modality for systematic evaluation of coronary atheroma structure and 
vasoreactive function in the same manner as IVUS.        
 
Limitations in our study should be acknowledged. First, the sample population is small 
and limited to patients with stable chest pain presentation. Second, we did not evaluate 
the impact of normal saline as an alternative agent to achieve blood clearance for 
optimal FD-OCT image acquisition. Next, our data is limited to the in vivo evaluation of 
coronary segments that do not contain angiographically significant stenosis. 
Consequently, our results may not be applied to segments with critical disease. Finally, 
a Doppler wire was not used during our vasodilatory assessment which would have 
provided incremental understanding between the changes in luminal volumes and its 
associated coronary blood flow/microvascular vasodilation.  
 
CONCLUSION 
Volumetric lumen assessment with OCT results in a smaller measurement compared to 
IVUS for a given epicardial segment analysed. Furthermore, in smaller vessels, a large 
measurement is seen when microvascular resistance is reduced. This finding is not 
related to underlying coronary plaque burden. As lumen size reduction and 
microvascular resistance occurs with significant epicardial coronary stenosis, this 
finding may have implications on stent sizing.
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TABLE 1: Clinical characteristics 
 Entire cohort (n=10) 








Calcium channel blocker 1 
Lipids, mmol/L  
Total cholesterol 4.73 ± 1.11 
TG 0.89 ± 0.45 
HDL 1.32 ± 0.34 
LDL 3.0 ± 0.91 





ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; 
TG = triglyceride; HDL = high density lipoprotein; LDL = low density lipoprotein; 
LAD = left anterior descending artery; LCx = left circumflex artery; RCA = right 
coronary artery  
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Corresponding horizontal views of IVUS (a) and OCT (c) imaging of the same coronary 
segment. Start frames (cross-sectional views) of IVUS and OCT shown in (b) and (d) 
respectively illustrating distal fiducial markers (white asterix). For IVUS, 9 consecutive 
cross sectional frames (yellow dotted lines, spaced at 0.5 mm intervals), and for OCT 
11 consecutive cross sectional frames (blue dotted lines, spaced at 0.4 mm intervals) 
were traced to depict each 4 mm coronary segment (Reproduced with permission from 
Puri et al. (Puri et al., 2012b)
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FIGURE 2: OCT-derived minimum lumen area (MLA) dichotomized into small 
lumen (top panel) and large lumen (below panel) with their corresponding graph.  
 
A & D represent the baseline MLA whereas B & E and C & F represent MLA in 
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Objectives: Plaque burden and endothelial dysfunction are both key pathological 
mechanisms associated with adverse coronary events. In this study, we aim to 
investigate the relationship between atherosclerotic lipid rich plaque and segmental 
coronary endothelial function utilizing near infrared spectroscopy (NIRS) in patients 
with stable chest pain presentation and acute coronary syndrome (ACS). 
Methods: 53 patients were enrolled. Coronary vessels with <30% visual angiographic 
disease were studied. If significant angiographic disease was identified, the ‘study’ 
artery was a non-culprit vessel. Macrovascular response [% change segmental lumen 
volume (SLV)], plaque burden [per cent atheroma volume (PAV)], lipid rich plaque 
(LRP), and lipid core burden index (LCBI) were studied in 2-mm coronary segments. 
Results: Segmental PAV (r = -0.41, p = 0.006), LRP (r = -0.165, p< 0.0001), and LCBI 
(r = -0.202, p< 0.0001) were significantly associated with endothelium independent 
vasoreactivity. Greater LRP (31.3% vs 17.8%, p = 0.0008) and LCBI (32 (90-214) vs 0 
(0-82), p = 0.0002) were observed in segments with impaired endothelium independent 
function whereas greater PAV was noted in the groups with both impaired endothelium 
dependent (32 [24.4-39.7]% vs 29.9 [12.4-38.3]%, p = 0.0013) and independent (35.7 
[28.2-46.5]% vs 30 [21.4-37.6]%, p = <0.0001) response when compared with normal 
segmental vasoreactivity. In a multivariate analysis, PAV was found to be the sole 
independent predictor for endothelium independent function (OR: 1.07; 95% CI: 1.04-
1.10, p < 0.0001). No association was observed between endothelial dependent function 
and any of the atheroma plaque indices. 
Conclusion: Our findings show that atheroma volume, and to a lesser extent, lipid rich 
necrotic core is linked with impaired coronary endothelial independent function. Further 
studies are required to determine if these segmental indices are associated with specific 
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Coronary endothelial dysfunction has been associated with adverse cardiac events, 
independent of traditional risk factors (Lerman and Zeiher, 2005). Similarly, in various 
large prospective trials, intravascular ultrasound (IVUS) derived plaque burden and its 
rate of progression are also known to be predictors of adverse cardiac outcomes (Stone 
et al., 2011, Stone et al., 2012, Nicholls et al., 2010). Previously, we described a novel 
methodology to evaluate segmental epicardial coronary endothelial function utilizing 
IVUS and intracoronary (IC) salbutamol infusion as the coronary endothelial dependent 
vasoreactive stimulus (Puri et al., 2012a). This study demonstrated a strong association 
between in vivo segmental epicardial endothelial dependent function and its underlying 
atheroma burden. Indeed, irrespective of clinical presentation whether patients 
presenting with stable chest pain syndrome or acute coronary syndrome (ACS), 
coronary atheroma plaque burden has been shown to be independently associated with 
coronary endothelial function (Puri et al., 2013). However, these studies did not explore 
the relationship between coronary endothelial function and plaque composition, notably 
qualitative and quantitative measurements of lipid within the plaque, thought a key 
factor of plaque vulnerability. 
 
Pathological studies have demonstrated thin cap fibroatheroma with lipid rich necrotic 
core as the substrate of plaque responsible for ACS (Virmani et al., 2006). Therefore, 
identifying and delineating such plaque characteristic in vivo may be important in 
improving patient’s risk assessment and management. A novel intracoronary catheter-
based near infrared spectroscopy (NIRS) imaging system has been developed to enable 
the detection of lipid rich containing plaque in vivo. This system, which now also co-
registers with IVUS, has undergone rigorous ex vivo (Gardner et al., 2008, Kang et al., 
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2015) and in vivo (Waxman et al., 2009) validation experiments and identifies lipid in 
coronary atheroma with a high degree of accuracy. The use of NIRS in the invasive 
coronary endothelial function assessment with quantitative coronary angiography 
(QCA) has been reported previously however it only included the left anterior 
descending (LAD) artery of patients with stable disease (Choi et al., 2013). We 
therefore sought to evaluate whether segmental coronary endothelial function, as 
assessed with IVUS, is associated with NIRS derived lipid rich plaque (LRP) and 





We consecutively enrolled 53 patients (age ≥ 18 years) who were referred to the Royal 
Adelaide Hospital Cardiac Catheterization Laboratories for diagnostic coronary 
angiography or percutaneous coronary intervention (PCI) for ACS or stable chest pain 
presentation. The target artery of interest must be “smooth” or have minimal disease, 
defined as <30% visual angiographic stenosis and not undergone previous PCI. If 
significant angiographic, culprit disease was identified, the study artery was the non-
culprit vessel. Informed consent was obtained >48 hours prior to index coronary 
angiography and all vasoactive medications were withheld 24 hours prior to the study. 
Exclusion criteria include previous surgical coronary revascularization, significant 
valvular heart disease or left ventricular systolic dysfunction (ejection fraction £ 35%), 
ST elevation myocardial infarction (STEMI), known predilection to coronary 
vasospasm, uncontrolled hypertension, significant renal or pulmonary disease, and 
chronic beta blocker therapy or use of long or short acting β2 agonist within the 
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previous 24 hours. This study was approved by the Royal Adelaide Hospital Research 
Ethics Committee (ACTRN12612000594820). 
 
Endothelial function assessment 
Coronary angiography was performed via a standard 6-French technique. Following 
this, coronary endothelial function was evaluated similar to our previously described 
methodology (Puri et al., 2012a). Should PCI be indicated, this was performed 
immediately after the completion of the endothelial function assessment protocol. 
Intravenous heparin (100 IU/kg) was administered for the research protocol. Briefly, a 
0.014-inch Doppler flow wire (FloWire; Volcano therapeutics Inc. Rancho Cordova, 
CA, USA) was placed in the proximal segment of the target artery and the average peak 
velocity (APV) of the coronary blood flow (CBF) was recorded. This wire was also 
used to monorail the 3.6F TVC Insight Catheter (InfraReDx, Burlington, Massachusetts, 
USA), a co-registration between IVUS and NIRS system, into the study artery. IVUS 
was performed according to standard protocol, without glyceryl trinitrate (GTN) pre-
treatment of the target artery. Serial 5-minute IC infusions via the guiding catheter at 2 
mL/min were administered in the following sequence: (a) 5% dextrose, (b) salbutamol 
(0.3 µg/min) to assess endothelium dependent vasodilation, and (c) bolus injection (not 
IC infusion) of GTN (100 µg) to assess endothelium-independent vasodilation. At 3 
minute into each IC infusion, we recorded the APV and the patient’s haemodynamics 
(blood pressure and heart rate) followed by repositioning of the wire into the distal 
vessel and commencement of IVUS pullback at 0.5mm/s. The infusion was then 




The method of IVUS grey scale evaluation was described previously (Puri et al., 2012a, 
Mintz et al., 2001). All grey scale data were analysed using echoPlaque 3.0.53 (Indec 
Systems, Santa Clara, CA, USA). Common distal and proximal fiduciary points 
(anatomical side branches) were chosen to match each IVUS run using ImageJ software. 
Cross sectional images were analysed every 16 frames (0.5mm) and each IVUS 
pullback was divided into a pre-defined 2mm segments comprising 5 cross sectional 
images at 0.5mm apart (Figure 1). Frames that precluded complete lumen or vessel wall 
planimetry were excluded from analysis, as were segments that involved branch points. 
The leading edge of the luminal borders and external elastic membrane (EEM) were 
contoured for each designated frame. Segmental percent atheroma volume (PAV) and 
percent change in segmental lumen volume (SLV) were the primary determinant of 
segmental plaque burden (Mintz et al., 2011)	and vasomotor response	respectively. 
Segmental PAV was calculated according to this equation:  
 
PAV =  Σ (EEMarea – lumenarea)segment  x 100  
  Σ (EEMarea)segment 
  
SLV was calculated as the average of lumen area within that particular segment and 
normalized as previously reported (Puri et al., 2012a). Impaired endothelial function is 
defined as % change SLV < 0 (vasoconstriction) whilst % change SLV > 0 denotes 
normal endothelial function (vasodilation) (Schachinger et al., 2000). The coronary 
blood flow (CBF) was calculated as: Average IVUS MLAentire vessel X (APV/2). Also at 
the vessel level, we collected the PAV for the entire vessel (PAVvessel), calculated 
according to the equation above except that it is the summation of plaque area and EEM 
area involving all the measured images in that vessel. The percent change CBF and 
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PAVvessel were the determinants of endothelial dependent microvascular function and 
the entire vessel plaque burden; these were explored in our secondary analysis. 
 
NIRS analyses 
During the NIRS automated pullback at 0.5mm/s, raw spectra were acquired at 40Hz, 
producing an image with data points spaced every 0.1 mm and every 10 apart. A NIRS 
algorithm defines a lipid containing plaque as fibroatheroma with lipid core >600 
circumferential extent, >200µm thick, with a fibrous cap having a mean thickness 
<450µm (Gardner et al., 2008). Using this algorithm, the position of lipid core in each 
scanned artery segment is plotted on a digital map or ‘chemogram’, whereby the x-axis 
denotes the pullback position (mm) and the y-axis represents the circumferential 
position (degree). The probability of lipid core presence is displayed in chemogram as a 
colour scale from red (low probability) to yellow (high probability). A summary metric 
(block chemogram) of lipid core presence in 2mm chemogram interval is also generated 
in 4 probability categories using the top 10th percentiles pixel information (yellow: P > 
0.98, tan: 0.84 ≤ P ≤ 0.98, orange: 0.57 ≤ P ≤ 0.84, red: P < 0.57) to enhance 
interpretation. A lipid core is considered to be present if at least one 2mm segment in 
the block chemogram contains a strong signal, i.e. bright yellow (>95% specificity). For 
our primary analysis, we defined segmental LRP as yellow or tan on the block 
chemogram (Kang et al., 2015). The final NIRS output is the lipid core burden index 
(LCBI), which is the quantitative measurement of lipid core and calculated by dividing 
the number of yellow pixels with the rest of viable NIRS pixel within the region of 
interest and scaled from 0-1000. We collected LCBI data at the segmental level (2mm) 
and also the total LCBI and maxLCBI4mm, which reflect LCBI information for the entire 
vessel. The NIRS images and the block chemogram were analysed off line using 
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LipiScan analyser software (LipiScan, InfraReDx, Burlington, MA, USA) (Figure 2).  
 
Statistical analysis 
Sample characteristics are summarized as counts and percentages; means with standard 
deviation or median with interquartile range as appropriate. Pearson correlation was 
performed to evaluate the linear association between coronary endothelial function and 
plaque burden. Spearman correlation was used to assess the association between 
coronary endothelial function and LRP and LCBI as well as between coronary 
microvascular function and total vessel LCBI and plaque burden. Differences between 
impaired versus normal coronary endothelial dependent and independent function or 
between stable and ACS patients were compared using Mann-Whitney rank sum test 
and intergroup data were analysed with the Kruskal-Wallis test.  
 
Univariate associations with the outcome of interest are reported as odds ratios. The 
estimates were obtained using a linear mixed effects model with a binomial distribution 
and a logit link function. Subjects were treated as a random factor in all analyses. 
Multivariate modelling started with a saturated model which included all variables with 
a univariate p-value < 0.2. Variables were systematically removed until only significant 
variables remained. All tests were two-tailed and assessed at the 5% alpha level. The 
analyses were completed using SAS v9.3 (SAS Institute Inc., Cary, NC, USA) and 




Patient Characteristics. Baseline demographics are shown in table 1. A total of 53 
patients were enrolled into the study. Two patients were excluded due to inability to 
acquire IVUS and NIRS data. One patient who presented with stable chest pain 
syndrome experienced complication attributable to IVUS catheter related clot at the end 
of the study protocol. This complication resulted in very small myocardial infarction. 28 
patients (53%) presented with stable clinical presentation and were found to have 
smooth coronary arteries. In our 51 patients, a total of 849 IVUS segments were 
available for greyscale IVUS analysis, and 789 segments were available for co-
registered greyscale and NIRS analysis. The mean length of the total vessel evaluated 
per patient was 37.54 ± 13.46mm (LAD 39.84 ± 14.73mm; LCx 32.51 ± 10.36mm; 
RCA 35.92 ± 9.29mm). The mean and median of segmental PAV was 31.79 ± 11.82% 
and 31.05 [12.28-77.35] % respectively. In the chemogram analysis, the median 
segmental LCBI was 0 [0-100] and 20% of the segments were LRP positive (Table 2).   
 
Relationship between segmental plaque burden, LRP, and conduit endothelial 
function. The median % change SLV was 2.61 [-4.16-10.36] % following IC 
salbutamol infusion and 15.81 [4.59-29.38] % following IC GTN administration. A 
linear association was not observed between salbutamol-mediated % change SLV and 
segmental PAV (r = -0.19, p = 0.221), LRP (r = -0.044, p = 0.213), or segmental LCBI 
(r = -0.056, p = 0.110). In contrast, significant correlation was observed between 
vasoreactive response to GTN with segmental PAV (r = -0.41, p = 0.006), LRP (r = -
0.165, p< 0.0001), and segmental LCBI (r = -0.202, p< 0.0001). Table 2 summarizes 
the IVUS greycale and NIRS data between different vasoreactive responses. Greater 
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PAV was found in the coronary segments with impaired vasoreactivity in response to 
both salbutamol (32 [24.4-39.7] % vs 29.9 [12.4-38.3] %, p = 0.0013) and GTN (35.7 
[28.2-46.5] % vs 30 [21.4-37.6] %, p = <0.0001). Similarly, segments with endothelial 
independent dysfunction were found to have higher percentage of LRP (31.3% vs 
17.8%, p = 0.0008), greater LCBI (32 [90-214] vs 0 [0-82], p = 0.0002), and smaller 
EEM area (12.1 [9.4-17.3] mm2 vs 15.6 [12.5-19.4] mm2, p <0.0001) when compared 
with segments with normal function. This observation was not noted following IC 
salbutamol infusion.  
 
We then conducted further analysis to see if this relationship held true at different 
amounts of plaque burden and LCBI measurements. Figure 3 and 4 describe the 
differences in segmental endothelium dependent and independent response in different 
tertiles of plaque burden and LCBI that were derived from the total coronary segments 
in the entire cohort. The consistent finding was that there was an inverse relationship in 
a dose dependent fashion between the burden of segmental conduit atherosclerosis and 
its lipid core with segmental coronary endothelium independent function whereby the 
segments in the lowest tertile of plaque exhibit the greatest vasodilation compared with 
the intermediate and highest tertile plaque and lipid group (Figure 5). This segmental 
plaque burden and lumen response relationship was also noted in the salbutamol group, 
albeit less, with no relationship demonstrated in different LCBI tertiles.   
 
Observer variability. The observer variability for grey scale IVUS measurement was 
high. The intraclass correlation of coefficient was 0.937 (95% CI: 0.863-0.971) and 
0.959 (0.885-0.985) for inter- and intra-observer variability respectively.      
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Coronary microvascular function and lipid rich plaque. The median % change CBF 
to salbutamol was 33.24 [10.77-54.17] %. There was no correlation observed between 
PAVvessel (r = 0.0446, p = 0.766), total LCBI (r = -0.0913, p = 0.556), and maxLCBI4mm 
(r = -0.1272, p = 0.411) with % change CBF in response to salbutamol. A significant 
correlation was noted between % change CBF and salbutamol mediated % change SLV 
(r = 0.36, p = 0.015). 
 
Multivariable predictors of segmental coronary endothelium dependent and 
independent function. Figure 6A and Table 3 summarizes the univariate and 
multivariate predictors for segmental coronary endothelial function in response to 
salbutamol. In the multivariate analysis, ACS presentation (OR: 0.43; 95% CI: 0.20-
0.95; p = 0.038), smoker (OR: 0.48; 95% CI: 0.23-1.00; p = 0.05), and reduced % 
change CBF (OR 0.99; 95% CI: 0.97-1.00; p = 0.034) were significantly predictive of 
impaired coronary vasoreactivity. Figure 6B summarizes the univariate predictors for 
GTN mediated segmental coronary vasoreactivity. The predictors for greater degree of 
endothelial independent function include negative LRP (OR: 0.54; 95% CI: 0.31-0.93; p 
= 0.026), lower LCBI (OR: 1.00; 95% CI: 1.00-1.00, p = 0.048), and lower segmental 
PAV (OR: 1.07; 95% CI: 1.04-1.09, p = 0.000). In the multivariate model, greater PAV 
was found to be the sole independent predictor for reduced luminal response to GTN 




Our study demonstrated that in coronary vessels with normal or minimal angiographic 
disease, segments which vasocontrict in response to salbutamol were not strongly 
associated with high-risk vulnerable plaque features. Similarly, % change of CBF in 
response to salbutamol, a determinant of microvascular endothelial function, was not 
related to total lipid or plaque burden. On the other hand, we found a strong inverse 
relationship between plaque burden, and to a lesser extent, LRP and LCBI, with respect 
to segmental vascular response to our endothelial independent vasodilator, GTN. 
 
Atherogenesis is a complex process which includes a dynamic interplay between 
multiple pathological factors including, but not restricted to inflammation, endothelial 
dysfunction, vascular smooth muscle cell (SMC) proliferation and apoptosis, lipid rich 
necrotic core formation, intraplaque haemorrhage, remodelling, and plaque rupture. It 
has been postulated that functional changes in the endothelium predates plaque and/or 
lipid formation (Ludmer et al., 1986). It is known that SMC also play a critical role in 
propagating the atherosclerotic process. For instance, in response to various local 
environmental cues, such as growth factors, inflammatory mediators, cell to cell or cell 
to matrix signaling, SMCs are able to undergo phenotypic modulation from its 
contractile to proliferative state in early stage atheroma formation (Shi and Chen, 2015). 
In addition, increased superoxide production by SMCs in response to oxidative stress 
impacts on the soluble guanylyl cyclase and cGMP-dependent protein kinase activity 
which in turn leads to eNOS uncoupling and endothelial dysfunction (Munzel et al., 
2005). Finally, SMCs and foam cells apoptosis and necrosis leads to lipid pool 
deposition and necrotic core formation (Virmani et al., 2000). Atherosclerosis, in 
essence, profoundly affects the vascular wall architecture and this structural and 
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chemical alteration may explain the variability in vascular response to exogenous 
stimuli.  
 
The present study did not find association between either lipid rich containing plaque or 
plaque burden with segmental vascular response to salbutamol, an endothelium-
dependent vasoreactive agent. This finding is indeed intriguing in light of previous 
findings (Puri et al., 2012a, Puri et al., 2015). We feel the cause of these discrepant 
findings is multifactorial. First, a single dose of 0.3 µg/min of salbutamol was used in 
this study compared with the incremental dosing of 0.15, 0.3, and then 0.6 µg/min used 
previously. Salbutamol possesses a half-life of 2-4 hours, therefore the lack of 
relationship between coronary salbutamol mediated vasoreactivity (SMV) and various 
plaque indices in our cohort might be due to salbutamol under dosing. We opted for the 
0.3 µg/min dose in the present study because this dose elicited the greatest response of 
SMV both at the conduit and microvascular level in our previous experiments (Puri et 
al., 2012a); it could be suggested that the reason for this maximal response may not 
necessarily be due to the 0.3 µg/min dose but rather as a result of cumulative dosing 
inclusive of the prior salbutamol (0.15 µg/min) infusion. This ‘under dosing’ theory is 
supported by the dynamic changes seen with our single dose strategy. The overall 
increase of % change SLV (2.61% vs 5.5%) and coronary blood flow (33.24% vs 54%), 
in response to salbutamol in the present study was lower when compared with our 
previous data (Puri et al., 2012a). Furthermore, the size of baseline SLV in the segments 
with impaired endothelium dependent function was larger when compared with 
segments with normal endothelium dependent luminal response (93.5 vs 80 mm3). It is 
thought that salbutamol mediates vasoreactivity by reducing coronary microvascular 
resistance and in part, through a shear stress mechanism, leading to conduit vessel 
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dilation (Barbato, 2009, Barbato et al., 2005). Since the relationship between shear 
stress and lumen is indirectly proportional (Davies, 2009), the lack of epicardial SMV 
demonstrated in our population may be due to greater baseline lumen, an observation 
we have noted previously (Sidharta et al., 2014, Puri et al., 2013). Interestingly, despite 
this apparent disagreement, we were able to demonstrate a strong linear relationship 
between coronary macro and microvascular endothelial dependent function. Also, 
patients who present with ACS or smoking history demonstrated greater degree of 
impaired coronary luminal response when compared with those who present with stable 
chest pain syndrome or non-smokers, an observation that was noted in previous 
coronary endothelial function studies (Bogaty et al., 1994, Zeiher et al., 1995). Taken 
together, this suggests that SMV reflects the systemic or generalized nature of 
atherosclerotic disease burden. Its conduit function however is dependent on shear 
stress generated by the coronary microvascular driving force and further influenced by 
epicardial lumen size.  
 
The inverse relationship between high-risk plaque features, such as plaque burden and 
to a certain extent, lipid rich necrotic core, with segmental endothelium independent 
function were not entirely unforeseen given the observation from previous studies 
(Adams et al., 1998, Schachinger and Zeiher, 1995). We are the first group to 
demonstrate the direct mechanistic link between these factors; especially the GTN 
vascular response’s association with specific plaque phenotype, NIRS derived LRP. 
Indeed, we showed that adjacent segments with various degree of plaque burden and/or 
lipid rich necrotic plaque exhibit abnormal endothelium independent function in a dose 
dependent manner irrespective of clinical presentation and traditional risk factors. In the 
clinical endothelial function assessment, GTN is normally administered to evaluate the 
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integrity of vascular SMC function given its direct, nitric oxide (NO) action at the 
epicardial level. However, results from previous in vivo observational studies regarding 
the role of endothelium independent function in the setting of coronary atherosclerosis 
have been conflicting, contrary to the general consensus regarding acetylcholine 
mediated luminal vasoreactivity. Whilst some groups noted impairment of nitroglycerin 
mediated dilation in patients with atherosclerotic risk factors (Adams et al., 1998) or 
minimal atherosclerotic disease (Schachinger and Zeiher, 1995), many others did not 
show this association (Ludmer et al., 1986, Lavi et al., 2009, Choi et al., 2013); leading 
to suggestion that vascular SMC function remains intact in spite of progressive 
endothelial dysfunction in various stages of atherosclerotic disease (Zeiher et al., 1991). 
In a sense, this is surprising given that vascular SMC has been shown to play a critical 
role in the pathogenesis of atherosclerosis even at the early stage. We believe the main 
difference observed above relates to the variability in GTN dosing. Indeed, to date there 
is no consensus as to what constitute the appropriate GTN dose in the evaluation of 
coronary endothelial function although majority of researchers seem to use an IC bolus 
dose of 200-300 microgram. In their IC GTN dose response experiment, Feldman et al. 
demonstrated that most epicardial coronary vasodilation usually occurred after 
relatively small doses of IC GTN, with two-thirds of the total dilation detected after 5 
µg and three-fourths after the cumulative dose of 55 µg (Feldman et al., 1982). Similar 
vasodilatory dose response was also shown in a non-invasive experiment, whereby 
sublingual GTN doses in the aforementioned range produces change in brachial artery 
diameter and other non-invasive NO mediated endothelial vasomotor parameters, such 
as radial artery or aorta augmentation index, comparable to that of the endothelium 
dependent stimuli at healthy subjects (Oliver et al., 2005). Taken together, only 
relatively small doses of IC GTN are required to produce significant coronary artery 
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dilatation; hence removing issues such as hypotension, which is not uncommonly seen 
with the higher doses. Furthermore, higher dose of GTN would theoretically assess the 
maximum vasodilator capacity (Emax), not a more appropriate EC50 effect required to 
correctly assess vascular smooth muscle function.  
 
Several other explanations may also be provided to explain the segmental impairment of 
GTN mediated vasodilation. In this study, segments with impaired endothelium 
independent vasoreactivity do not only have greater plaque burden and lipid core but 
also smaller EEM area compared to the segments which exhibit normal vascular 
response (12.1 vs 15.6 mm2). Although this is likely due to plaque-related negative 
remodelling, it is also plausible that the smaller EEM area may represent reduced 
baseline vasomotor tone as a reflection of segmental functional remodelling process 
(Schachinger and Zeiher, 1995). Second, the impairment in GTN vasodilator capacity 
may also due to vascular NO resistance. Reduced or non-responsiveness to GTN, 
distinguishable from nitrate tolerance, has been reported in patients with congestive 
heart failure (Varriale et al., 1991), stable angina, or ACS (Chirkov et al., 2001) and 
may extend beyond vascular smooth muscle and include platelets. Predominant 
mechanisms of NO resistance include reduction of soluble guanylate cyclase activity or 
inactivation of NO by superoxide anion production (Chirkov et al., 2001). Lastly, 
smooth muscle cell dysfunction secondary to SMC atrophy and/or apoptosis in 
conjunction with extracellular matrix deposition at the intima occurs in the 
atherosclerotic process and these architectural changes alone may impact on the GTN 
vasomotor response (Adams et al., 1998). Taken together, our findings suggest: (1) 
early in the process of atherogenesis, structural and functional changes are not limited at 
the endothelium level alone but also involves the vascular SMC; (2) the extent of plaque 
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burden and to a lesser extent, lipid rich necrotic core, predicts GTN vasodilator capacity 
irrespective of traditional risk factors; (3) concerning evaluation of the NO mediated 
effects on the epicardial vascular SMC, irrespective of being endogenous driven (via 
shear stress or direct conduit effects) or exogenous directed (NO donor), appropriate 
dosing of vasoactive agent may be critical to achieve the desirable response.  
 
Limitations. Given the invasive nature of our study protocol and the potential for 
inducing coronary vasospasm, we only performed the endothelial function assessment 
in the non-culprit artery with normal appearance or mild angiographic disease; hence 
these findings should be repeated in culprit segments with greater plaque burden.  
Secondly, due to the constraint and difficulties with conducting true dose response 
effects in human coronary arteries, only a single dose of salbutamol and GTN were used 
in this study. Finally, in contrast to relatively well-accepted algorithm for necrotic core 
identification in VH-IVUS, to date, there is no consensus of what constitute NIRS 
derived lipid rich plaque. For instance, in their endothelial function analysis, Choi and 
colleague (Choi et al., 2013) defined lipid core plaque as orange, tan, and yellow on 
block chemogram, contrary to our LRP definition, which only included tan and yellow 
colour on block chemogram (Kang et al., 2015).  
 
CONCLUSION  
This study further adds to the growing body of evidence linking plaque burden and 
certain aggressive plaque phenotype, such as lipid rich necrotic core with impaired 
segmental vascular function. The strong inverse relationship between segmental 
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endothelium independent function with high-risk plaque feature was a novel 
mechanistic observation and may offer a proof of concept of a simpler methodology to 
evaluate coronary endothelial function. Further studies will need to be undertaken to 
evaluate if a simple readily available drug (IC GTN) can provide incremental risk 
predictive information regarding focal coronary atheroma identified in the invasive 
catheterization laboratory. 
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FIGURE LEGENDS 
Figure 1. Methodology for grey scale intravascular ultrasound and NIRS analysis. The 
IVUS pullback was divided into 2-mm segments (denoted by red lines on longitudinal 
view). Within each segment, plaque, and lumen volumes were calculated upon 
sequential numbered frames spaced 0.5 mm apart, numbered 1–5 (cross-sectional 
views).  
 
Figure 2. Near infrared spectroscopy output with the corresponding greyscale image 
(left). (Top right) Chemogram map of the artery wall indicating the location and 
intensity of lipid core plaque. (Middle right) Block chemogram displaying the presence 
of lipid core at 2mm segments in four probability categories (red<orange<tan<yellow). 
The lipid core burden index (LCBI) of the region of interest (subtended by the blue 
lines) is 197, with max(LCBI)4mm of 442.  
 
Figure 3. Segmental endothelial dependent and independent vasoreactivity stratified 
according to different plaque burden tertile. Data are expressed as median. 
 
Figure 4. Segmental endothelial dependent and independent vasoreactivity stratified 
according to different LCBI tertile. Data are expressed as median. 
 
Figure 5. Representative images and changes to minimal luminal area (MLA) following 
intracoronary glyceryl trinitrate (GTN) administration. Panel A represents a segment with 
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high plaque burden/LRP positive with corresponding lack of vasodilator response seen in 
the same segment to GTN seen in Panel B. Panel C shows a segment with low plaque 
burden/LRP negative with a strong vasodilator response seen in the same segment to GTN 
seen in Panel D. 
 
Figure 6. Forest plot summarizing the univariate predictors of (A) segmental coronary 





TABLE 1. Clinical, biochemical, and angiographic characteristics 
Clinical Characteristics n =53 
Age 60.1 ± 8.97 
Female 23 (43%) 
Clinical Presentation:  
Stable (smooth coronaries) 28 (53%) 
Stable (with culprit) 9 (17%) 
ACS 16 (30%) 
Artery:  
Left anterior descending 33 (62%) 
Left circumflex 15 (28%) 
Right coronary artery 5 (10%) 
Current smoking 30 (57%) 
Diabetes 10 (19%) 
Hypertension 37 (70%) 
Hyperlipidaemia 38 (72%) 
Medications:  
Aspirin 46 (87%) 
ACE inhibitors / ARB’s 34 (64%) 
Statins 37 (70%) 
Calcium channel blocker 9 (17%) 
Nitrate 1 (1.9%) 
Total cholesterol (mmol/L) 4.54 ± 1.5 
Low density lipoprotein cholesterol (mmol/L) 2.89 ± 1.1 
High density lipoprotein cholesterol (mmol/L) 1.0 [0.9-1.3] 
Triglyceride (mmol/L) 1.3 [0.6-2] 
C-reactive protein (mg/L) 3.5 [0.85-9.05] 
Brain natriuretic peptide (ng/L) 98 [50-283] 
Data are expressed as mean ± SD or median and interquartile range when appropriate 
ACS, Acute Coronary Syndrome - defined as troponin positive presentation; ARB 
Angiotension Receptor Blocker 
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Table 2.  Segmental grey-scale and NIRS data according to the pattern of coronary 





% change SLV 
(SALBUTAMOL) 
% change SLV (GTN) 
Impaired Normal P 
value 




















































LRP (%) 20 23.1 18.1 0.09 31.3 17.8 0.0008 
LCBI 0 [0-100] 0 [0-130] 0 [0-83] 0.33 32 [0-
214] 
0 [0-82] 0.0002 
Data are expressed as median [interquartile range]. 
SLV, Segmental Lumen Volume; PAV, Percent Atheroma Volume; EEM, External 
Elastic Media; LRP, Lipid Rich Plaque; LCBI, Lipid Core Burden Index 
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TABLE 3. Multivariate analysis for % change in SLV 
Effect Odds ratio Lower CL Upper CL P value 
Stable presentation 0.43 0.2 0.95 0.038 
Non smoker 0.48 0.23 1.0 0.05 
% change CBF 0.99 0.97 1.0 0.034 
PAV* 1.07 1.04 1.10 <0.0001 
*Independent predictor for endothelium independent response 





































































Low PAV (12.28 - 25%)
Intermediate PAV (25.5-35.8%)




*P<0.01 vs low PAV
#P<0.01 vs intermediate PAV




































Low LCBI: 0-0 Intermediate LCBI: 0-45 High LCBI: 45-717  
*
*#
*p<0.001 vs low GTN
#p<0.05 vs intermediate GTN
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CHAPTER 5: THE INVESTIGATION OF THE RELATIONSHIP 
BETWEEN SEGMENTAL CORONARY ENDOTHELIAL 
FUNCTION AND ATHEROSCLEROTIC PLAQUE 
PROGRESSION/REGRESSION 
 
Adapted from: Sidharta SL, Baillie TJ, Howell S, Nicholls SJ, Montarello N, Honda S, 
Shishikura D, Delacroix S, Beltrame JF, Psaltis PJ, Worthley SG, Worthley MI. In vivo 
evaluation of human coronary structure-function predicts subsequent progression of 
coronary atherosclerotic plaques: A Near Infrared Spectroscopy Study (submitted to 
European Heart Journal). 
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Background: Coronary vasodilator function and atherosclerotic plaque progression 
have both been shown to be associated with adverse cardiovascular events. However, 
the relationship between these factors and the lipid burden of coronary plaque remains 
unknown. These experiments focus on investigating the relationship between impaired 
coronary vasodilator function [endothelium dependent (salbutamol) and endothelium 
independent (glyceryl trinitrate, GTN)] and the natural history of lipid rich plaque 
(LRP). 
Methods and results: 33 patients with stable chest pain syndrome or acute coronary 
syndrome underwent serial assessment of coronary vasodilator function and plaque 
imaging by dual modality intravascular ultrasound (IVUS) and near infrared 
spectroscopy (NIRS). Coronary segmental macrovascular response [% change 
segmental lumen volume (△SLV)], plaque burden [per cent atheroma volume (PAV)], 
and lipid core [LRP and lipid core burden index (LCBI)] were measured at baseline and 
after an interval of 12-18 months (N=520 segments). Coronary segments which develop 
LRP over the study time period demonstrated greater reduction in vasodilator response 
to salbutamol (-0.24 ± 2.96 vs 5.60 ± 1.47%, p = 0.04) and GTN (13.91 ± 4.45 vs 21.19 
± 3.19%, p = 0.036), at baseline. By multivariate analysis, reduced baseline coronary 
endothelium dependent vasodilator function independently predicted increase in lipid 
core whereas baseline coronary endothelium independent predicted increase on 
atheroma volume. In the secondary analysis, serial changes in coronary endothelial 
independent function was associated with changes in plaque volume.  
Conclusions: Epicardial coronary vasodilator function is a major determinant of LRP 
progression irrespective of the nature of clinical presentation.  
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Coronary heart disease is the leading cause of death in the western world, accounting 
for 1 in 7 deaths in the United States (Writing Group et al., 2016). This underscores the 
importance of identifying ‘at risk’ or vulnerable patients who are likely to develop 
future adverse cardiac events. The pathogenesis of acute coronary syndrome (ACS) 
nevertheless is complex and remains to be fully elucidated. Altered vasodilator function 
or vascular nitric oxide resistance measured in both peripheral (Neunteufl et al., 2000, 
Yeboah et al., 2009)	and coronary circulation (Halcox et al., 2002, Schachinger et al., 
2000, Suwaidi et al., 2000) has been shown to be associated with future adverse cardiac 
events, independent of traditional cardiovascular risk factors. However, the exact 
mechanism behind how this impacts on clinical events remains uncertain.  
 
In the past few years, data from several prospective trials have identified plaque burden 
and certain plaque characteristics, such as virtual histology (VH) derived thin cap 
fibroatheroma and minimum lumen area, as independent predictors of adverse events; 
which applies to culprit and non-culprit vessels (Stone et al., 2011, Cheng et al., 2014, 
Calvert et al., 2011, Stone et al., 2012, Nicholls et al., 2010). Utilizing intravascular 
ultrasound (IVUS), we demonstrated a strong relationship between in-vivo segmental 
human coronary endothelial dependent conduit function and underlying atheroma 
burden (Puri et al., 2012a). This coronary structure-function relationship holds true 
regardless the nature of patient’s clinical presentation (Puri et al., 2013).  
 
However, these studies have not evaluated the impact of this dynamic process on the 
natural history of plaque burden or composition over time. One characteristic of plaque 
that has gained increasing recent attention as a marker of vulnerability is its lipid 
	 137 
content. Near infrared spectroscopy (NIRS) technology has greatly improved the ability 
to detect and quantify lipid rich necrotic core in real time and can be acquired at the 
same time as gray scale IVUS images, using dual modality catheter systems. Studies 
have shown that lipid rich plaque (LRP) is a key pathological substrate of ACS 
(Gardner et al., 2008, Waxman et al., 2009). We have undertaken this study, using serial 
NIRS-IVUS imaging to assess the impact of coronary vasodilator function on the 




This study was approved by the Royal Adelaide Hospital Research Ethics Committee 
and registered with Australian New Zealand Clinical Trials Registry 
(ACTRN12612000594820). We consecutively enrolled patients (age ≥ 18 years) who 
were referred to the Royal Adelaide Hospital Cardiac Catheterization Laboratories for 
diagnostic coronary angiography and/or percutaneous coronary intervention (PCI) with 
ACS or stable chest pain presentation. Each patient underwent a clinical evaluation and 
IVUS/NIRS study protocol at baseline and at 12-18 month follow-up. The evaluated 
artery had to be angiographically “smooth” or containing only minimal disease, defined 
as <30% visual angiographic stenosis, with no previous percutaneous coronary 
intervention (PCI) undertaking to it. If a significant angiographic, culprit artery was 
found, the study artery was a non-culprit vessel. Informed consent was obtained >48 
hours prior to index coronary angiography and all vasoactive medications were 
withheld 24 hours prior to the study. Exclusion criteria included previous surgical 
coronary revascularization, significant valvular heart disease or left ventricular systolic 
dysfunction (ejection fraction ≤ 35%), ST elevation myocardial infarction (STEMI), 
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known predilection to coronary vasospasm, uncontrolled hypertension, significant renal 
or pulmonary disease, and chronic beta blocker therapy or use of long or short acting β2 
agonist within the previous 24 hours.  
 
Coronary vasodilator function testing 
Coronary angiography was performed according to standard clinical indication. Upon 
arterial sheath insertion, 25 mL of blood was collected for measurement of lipid profile, 
brain natriuretic peptide (BNP) and C-reactive protein (CRP). Lipid profile was also 
measured at follow-up. Following completion of angiography, coronary endothelial 
function was evaluated similar to our previously described methodology (Puri et al., 
2012a). If PCI to culprit vessel was indicated, this was performed immediately after the 
endothelial function testing. Intravenous heparin (100 IU/kg) was administered for the 
research protocol. Briefly, the 3.6F TVC Insight Catheter (InfraReDx, Burlington, 
Massachusetts, USA) was inserted into the study artery. IVUS was performed according 
to standard protocol, without glyceryl trinitrate (GTN) pre-treatment of the target artery. 
Serial 5-minute intracoronary (IC) infusions via the guiding catheter at 2 mL/min were 
administered in the following sequence: (a) 5% dextrose, (b) salbutamol (0.3 µg/min) to 
assess the endothelium dependent vasodilation, and (c) bolus injection of GTN (100 
mcg) to assess endothelium independent vasodilation. At 3 minute into each IC 
infusion, we recorded the patient’s hemodynamics (blood pressure and heart rate) 
followed by commencement of IVUS-NIRS pullback at a rate of 0.5mm/s. The infusion 
was then continued throughout the remaining 2 minutes that it took for IVUS-NIRS 




All gray scale IVUS data were analysed using echoPlaque 3.0.53 (Indec Systems, Santa 
Clara, CA, USA) using previous methodology (Puri et al., 2012a). Common distal and 
proximal fiduciary points (anatomical side branches) were chosen to match baseline and 
follow-up IVUS runs using ImageJ software (Mintz et al., 2011). Cross sectional 
images were analysed every 16 frames (0.5mm) and each IVUS pullback was divided 
into a pre-defined 2-mm segments comprising 5 cross sectional images at 0.5mm apart; 
the 2-mm segment was selected to allow for co-registration analysis with the NIRS 
output both at baseline and during follow-up. Frames that precluded complete lumen or 
vessel wall planimetry were excluded from analysis, as were segments that involved 
branch points. Manual planimetry of the leading edge of the luminal borders and 
external elastic membrane (EEM) were performed for each designated frame. 
Segmental percent atheroma volume (PAV) and percent change in segmental lumen 
volume (△SLV) were used to determine segmental plaque burden and vasomotor 
response	respectively. Segmental PAV was calculated according to the following 
equation: 
 
PAV =  Σ (EEMarea – lumenarea)segment  x 100  
  Σ (EEMarea)segment 
  
SLV was calculated as the average of lumen area within that particular segment and 
normalized as previously reported (Puri et al., 2012a). Remodelling index (RI) was 
calculated as EEM at follow-up minus EEM at baseline (Mintz et al., 2011).  
 
NIRS analyses 
A NIRS algorithm defines a lipid containing plaque as fibroatheroma when the lipid 
core is >600 circumferential extent, >200µm thick, and a fibrous cap mean thickness of 
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<450µm (Gardner et al., 2008). Using this algorithm, the position of lipid core in each 
scanned artery segment is plotted on a digital map or ‘chemogram’, whereby the x-axis 
indicates the pullback position (mm) and the y-axis represents the circumferential 
position (degree). The probability of lipid core presence is displayed in a chemogram as 
a colour scale from red (low probability) to yellow (high probability). To enhance 
interpretation, another NIRS output called block chemogram is generated, which is a 
summary metric of lipid core presence in 2-mm chemogram intervals; it is classified in 
4 probability categories using the top 10th percentiles pixel information (yellow: P > 
0.98, tan: 0.84 ≤ P ≤ 0.98, orange: 0.57 ≤ P ≤ 0.84, red: P < 0.57). For our primary 
analysis, we defined segmental LRP as yellow or tan on the block chemogram (Kang et 
al., 2015). The final NIRS output is lipid core burden index (LCBI), which is the 
‘quantitative measurement’ of lipid output and derived from a fraction of valid yellow 
pixels within a longitudinal range of the chemogram and scaled from 0-1000. The NIRS 
images and the block chemogram were analysed off line using LipiScan analyser 
software (LipiScan, InfraReDx, Burlington, MA, USA).  
 
Statistical analysis 
Categorical measures were summarized as counts and percentages; continuous data 
were summarized as means with standard deviation and medians with interquartile 
range as appropriate. Differences between baseline and follow-up data were made using 
Student t test for the patients’ biochemical and clinical parameters, and mixed models 
for segmental variables (LCBI, PAV, SLV, EEM). Segments were also stratified 
according to their baseline LRP (derived from block chemogram) and ‘progressor’ 
status as measured by changes in LCBI (LCBI). Adjusted means were calculated for 
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each group for △SLV, SLV, PAV, EEM, and RI using mixed models, accounting for 
multiple segments measurements within a patient. 
 
In constructing multivariate predictor model, LRP was treated as a dichotomous 
measure and analysed using a linear mixed effects model with a binomial distribution 
and a logit link function. The remaining outcomes were assessed as continuous 
measures using linear mixed effects models with a Gaussian distribution and an identity 
link function. Subject was treated as random factor in all models. Multivariable 
modelling started with a fully saturated model which included all variables with a p-
value less than 0.20. Variables were then systematically removed from the model until 
only significantly variables remained. All tests were two-tailed and assessed at the 5% 
alpha level. The analyses were completed using SAS v9.3 (SAS Institute Inc., Cary, 
NC, USA) and GraphPad Prism v6 (La Jolla, CA, USA).  
 
RESULTS  
Patient characteristics. Baseline demographics are summarized in table 1. From 4th 
March 2013 – 12th January 2015, 51 patients were enrolled into the study. Complete 
follow-up IVUS/NIRS data were obtained from 33 patients, with mean follow-up 
duration of 15 ± 3.8 months. During baseline imaging, one patient developed procedural 
complication due to IVUS catheter related clot at the end of the study protocol. The 
complication resulted in small myocardial infarction with no regional wall motion 
abnormality detected. This patient was excluded from the analysis. Five patients who 
were studied at baseline developed adverse events during follow-up, unrelated to study 
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protocol, with 1 death and 4 target vessel intervention (to the study vessel) due to stable 
angina (2 patients) and unstable angina (2 patients).  
 
61% patients had smooth coronary arteries and presented with stable chest pain 
syndrome at baseline and 30% presented with ACS. The left anterior descending (LAD) 
artery was studied in 58%. The mean length of the coronary vessel evaluated per patient 
was 37.85 ± 13.10mm (LAD 40.43 ± 14.22mm; LCx 32.42 ± 11.34mm; RCA 41.40 ± 
6.32mm). The mean total cholesterol, HDL-C, and triglyceride at follow-up were 3.97 ± 
0.24 mmol/L (p < 0.05 vs baseline), 1.04 ± 0.04 mmol/L (p < 0.05 vs baseline), and 
1.06 ± 0.13 mmol/L  (p < 0.01 vs baseline) respectively, representing an absolute 
differences of -0.62 ± 1.42, -0.09 ± 0.21, and -0.55 ± 1.17 from baseline. There was no 
difference in the level of LDL-C (2.74 ± 0.2 vs 2.45 ± 0.16, p = 0.13), systolic (129.6 ± 
3.71 vs 133.1 ± 3.69, p = 0.41), and diastolic blood pressure (77.66 ± 1.76 vs 77.94 ± 
1.67, p = 0.89) between baseline and follow-up. 
 
Baseline coronary vasodilator function and follow-up LRP. Table 2 summarizes all 
coronary segments according to its LRP status at baseline. A total of 520 paired 2-mm 
segments were available for complete baseline and follow-up IVUS and NIRS analysis. 
Of these, 412 (79%) did not have LRP at baseline. During follow-up, 35 segments (8%) 
progressed to develop LRP whilst 377 segments remained LRP negative (Figure 1). The 
coronary segments which eventually progressed demonstrated impaired vasodilator 
function in response to salbutamol  
(-0.24 ± 2.96 vs 5.6 ± 1.47%, p = 0.04) and GTN (13.91 ± 4.45 vs 21.19 ± 3.19%, p = 
0.036) (Figure 2 & 3)  as well as greater PAV (34.35 ± 2.01 vs 29.57 ± 1.52%, p = 
0.001) and LCBI (76.33 [67.48-83.05] vs 19.32 [12.09-26.43], p = 0.0001) at baseline.  
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On the other hand, amongst the segments which contained lipid core at baseline, 40% 
“healed” during follow-up. When compared with the segments which remained LRP 
positive at follow-up imaging, these segments were noted to have smaller LCBI (235 
[219-291] vs 326 [288-386], p = 0.002) and a statistical trend to smaller PAV (38.6 ± 
2.67 vs 42.59 ± 2.51%, p = 0.097) at baseline. There was no statistical difference in the 
baseline vasomotor response between LRP segments which healed compared to those 
that did not (salbutamol: 5.57 ± 2.77 vs 4.95 ± 2.63%, p = 0.79; GTN: 14.05 ± 3.39 vs 
9.88 ± 3.03%, p = 0.235) (Figure 2). 
 
The univariate predictors of follow-up LRP are summarized in figure 4. Every 5-unit 
reduction in baseline salbutamol-mediated vasomotor (SMV) response was associated 
with 11% increase in the odds of developing positive LRP during follow-up. On 
multivariate analysis, only the baseline LCBI (OR: 1.24, 95% CI (1.17 to 1.31), p < 
0.0001) and changes in LCBI (OR: 1.29, 95% CI (1.22 to 1.37), p < 0.0001) were 
independent predictors of follow-up LRP.  
 
Baseline coronary vasodilator function, changes in LCBI, and changes in PAV. 
Table 3 summarizes the mean and median of segmental LCBI and PAV at baseline and 
follow-up. When the groups were dichotomized into ‘non-progressor’ (D LCBI £ 0) vs 
‘progressor’ (D LCBI > 0) on the basis of changes in LCBI, the ‘progressor’ group was 
noted to have smaller baseline lumen and EEM, and greater PAV and remodelling index 
(Fig 5). Furthermore, there was no difference in the baseline vasoreactive response 
between the two groups. In the multivariable prediction analysis however, reduced 
baseline SMV response (b coefficient: -3.03, 95% CI (-5.81 to -0.25), p = 0.033) was 
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associated with greater changes in LCBI as were segmental LCBI (b coefficient: -5.10, 
95% CI (-5.75 to -4.46), p < 0.001), PAV (b coefficient: 12.65, 95% CI (7.80 to 17.51), 
p < 0.001) and remodelling index (b coefficient: 6.36, 95% CI (0.77 to 11.95), p = 
0.026) (Table 4). 
 
No relationship between changes in PAV and changes in LCBI was seen (b coefficient -
0.35, 95% CI (-2.24 to 1.55), p = 0.721). In the multivariate analysis, changes in PAV 
was significantly associated with baseline GTN-mediated vasoreactive function 
whereby every 5-unit increase in vasodilation was associated with an 0.21-unit increase 
in mean changes in PAV. Similarly, changes in PAV was associated with baseline 
LCBI (b coefficient: 0.07, 95% CI (0.04 to 0.10), p < 0.0001) (Table 5). 
 
Changes in coronary vasodilator function, changes in LCBI, and changes in PAV. 
Due to the disparity in the manner baseline coronary endothelial dependent and 
independent function affecting either plaque composition or atheroma volume 
progression, we performed secondary analysis to determine whether these relationships 
were indeed related to the predictive nature of coronary endothelial function or merely 
an associated phenomenon. Complete serial coronary endothelial function at baseline 
and follow-up were available in 25 out of 33 patients (454 segments). Following 
adjustment for baseline coronary vasoreactive response, lumen volume, plaque burden, 
and segmental LCBI; changes in LCBI was not associated with either changes in serial 
vasomotion in response to salbutamol (b coefficient: -0.65, 95% CI (-1.36 to 0.05), p = 
0.07) or GTN (b coefficient: -0.2, 95% CI (-0.75 to 0.35), p = 0.477). Changes in PAV, 
on the other hand, was significantly associated with changes in serial vasoreactivity in 
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response to GTN (b coefficient: -0.06, 95% CI (-0.09 to -0.02), p = 0.001) but not 
salbutamol (b coefficient: 0.01, 95% CI (-0.03 to 0.05), p = 0.671). 
 
DISCUSION 
The salient findings of this serial IVUS-NIRS study were: (i) epicardial coronary 
endothelium dependent vasodilator function is a major determinant and predictor of 
LRP progression; (ii) serial changes in coronary GTN vasomotor response is associated 
with atherosclerotic burden progression but not changes in plaque composition; (iii) the 
natural history of coronary atherosclerosis in vivo is dynamic with potential to progress 
or heal.  
 
Coronary vasodilator function and atherosclerotic plaque progression. Coronary 
endothelium vasodilator dysfunction has been proposed as the key component in the 
pathophysiology of ACS given its association with various traditional risk factors of 
atherosclerosis (Zeiher et al., 1995, Drexler and Zeiher, 1991), unstable clinical 
presentation (Bogaty et al., 1994), and future adverse cardiac events (Halcox et al., 
2002, Schachinger et al., 2000, Suwaidi et al., 2000). In spite of this, the mechanistic 
links which provide plausible explanation between altered vascular function and clinical 
events have not been fully elucidated. Several investigators, including us have 
demonstrated that coronary vasoreactivity in response to either acetylcholine, 
salbutamol, or GTN is significantly impaired in coronary segments which exhibit 
‘vulnerable plaque’ features, such as high plaque burden (Puri et al., 2012a, 
Schachinger and Zeiher, 1995), necrotic core (Lavi et al., 2009), and inflammation 
(Choi et al., 2014). Others have shown that nitric oxide resistance is also associated 
with increased platelet aggregation (Chirkov et al., 2001) and reduction in the acute 
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fibrinolytic activity (Newby et al., 1999). Collectively, these findings provide a 
rationale linking altered nitric oxide mediated vascular function with adverse cardiac 
events. However, these studies lacked serial evaluation of these surrogate markers to 
validate the effects of vasomotor function on plaque biology over time. In this present 
study, we demonstrated for the first time that in the ‘near normal’ non-culprit artery of 
the patients who present with either stable chest pain syndrome or ACS, impaired 
endothelium dependent vasodilator function is an independent predictor of 
atherosclerotic LRP progression, irrespective of the nature of their clinical presentation. 
Importantly, coronary endothelial function remained an independent predictor of 
disease progression even after controlling for other ‘vulnerable plaque’ features, such as 
plaque burden, LCBI, and remodelling index. These findings therefore would support 
the notion that coronary endothelium dependent vasodilator dysfunction occurs early in 
the process of atherogenesis and play a crucial role in the acceleration of atheroma 
necrotic core formation and progression.  
 
Coronary endothelium independent vasoreactivity, on the other hand, is not associated 
with plaque composition evolution but with plaque volume progression in a direct, 
linear fashion. Of note, we did not observe any association between coronary SMV and 
atheroma burden progression. Previous reports have documented that the greatest 
degree of plaque progression tend to occur in subjects with the least amount of plaque at 
baseline (Nicholls et al., 2010, Nicholls et al., 2006). Second, PAV, which is commonly 
accepted as the primary determinant of plaque burden in various randomized trials 
(Mintz et al., 2011), expresses atheroma volume in proportion to the EEM volume 
(Nicholls et al., 2007). Consequently, the association between endothelium independent 
response and changes in plaque volume in this study may in fact reflect the degree of 
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underlying plaque burden and arterial remodelling, leading to increased vessel wall 
stiffness. To explore this interaction further and to establish whether this coronary 
structure-function relationship is of predictive nature or merely an associated 
phenomenon, we conducted a secondary analysis on a subset of patients who had 
complete baseline and follow-up endothelial function assessment. We discovered that 
serial changes in GTN-mediated vasoreactive response were inversely correlated with 
plaque burden progression, not with plaque composition evolution, suggesting that 
coronary endothelium dependent vasodilator function mediates the progressive activity 
of atherosclerosis; the relationship between plaque growth and coronary endothelium 
independent vasomotor response however seems to be an associated phenomenon.  
 
Dynamic nature of coronary atherosclerosis. Data from serial VH-IVUS studies have 
shed some light on the dynamic nature of coronary lesions (Kubo et al., 2010). 
Consistent with this observation, we found that coronary segments with certain 
environmental atheroma milieu demonstrate propensity to progress or heal. Yet, it is 
worth commenting that the trajectory of the plaque compositional changes in this 
present study does not seem to correlate with the changes in atheroma thickness. This 
finding is indeed intriguing in light of the previous statin trials which showed that 
regression of plaque volume tends to be accompanied by the change in plaque 
composition (Hong et al., 2009). Several possible conjectures may be provided to 
explain these findings. First, this study is a non-interventional, natural history 
observational study. Not surprisingly, the change in plaque volume is minimal and may 
not be substantial enough to detect the association signal with the corresponding plaque 
characteristics. Furthermore, plaque compositional change tends to precede the change 
in atheroma burden (Dohi et al., 2015). Indeed, pathology data indicated that plaque 
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growth occurs as a result of recurrent events of plaque disruption followed by healing 
(Mann and Davies, 1999); a process downstream to necrotic core formation, which is 
characterized by non-resolving inflammation, macrophage infiltration, and foam and 
smooth muscle cells (SMC) apoptosis (Virmani et al., 2000). Incidentally, NIRS LRP 
positive lesions are not only known to contain rich free cholesterol monohydrate and 
cholesterol ester but also heightened inflammatory and apoptotic cellular activity within 
the plaque and fibrous cap (Virmani, 2011, Patel et al., 2013). Lastly, the disparity in 
the plaque growth-characteristic relationship may reflect the dynamic interplay between 
the coronary endothelium-SMC complex in mediating atherosclerotic progression as 
demonstrated by the varying coronary endothelium dependent and independent 
response shown in this study.  
 
Clinical implications. NIRS has emerged as an attractive intravascular imaging option 
in clinical setting due to its ability in detecting lipid component of fibroatheroma, which 
may yield important prognostic information (Oemrawsingh et al., 2014). Hence, serial 
NIRS imaging may be useful in generating novel clinical surrogate marker in the same 
manner as serial IVUS has done in the past. Although our study is not designed or 
powered to detect hard clinical endpoint, its results have provided some rationale 
explaining the mechanistic relationship between coronary vasoreactive response and the 
natural history of atherosclerosis. We postulate that ‘near-normal’ coronary segments 
with impaired endothelial function and LRP are at higher risk to progress to flow 
limiting stenosis, plaque rupture, and increased clinical events. All in all, the use of 
coronary structure-function assessment may serve as an important prognostic tool to 
identify segments with early accelerated and progressive atherosclerosis, and as a means 
to monitor disease activity (Kitta et al., 2009) above and beyond traditional 
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cardiovascular risk factor score. However, its widespread clinical use would solely 
depend on the validation of the findings of this invasive study with its non-invasive 
imaging modalities equivalent.  
 
Limitation. Some limitations of this study need to be acknowledged. First, the 
relatively small number of patients and adverse cardiac events did not allow us to 
evaluate whether coronary vasodilator function or changes in LCBI relate to clinical 
outcomes. Second, given the invasive nature of our study protocol and the potential for 
inducing coronary vasospasm, we only performed the endothelial function assessment 
in the non-culprit artery with normal appearance or mild angiographic disease and 
hence these findings should not be extrapolated to segments with greater plaque burden 
or culprit lesions. Thirdly, due to time limitations with an invasive protocol, only a 
single dose of salbutamol and GTN were used in this study, where a formal dose 
assessment would have been more appropriate. Fourth, we only included patients who 
are clinically stable given that all vasoactive agents, including anti anginals such as 
beta-blocker and nitrate therapy needed to be withheld prior to the procedure; in this 
way, allowing for a potential selection bias to a more stable cohort.  
 
CONCLUSION 
This study adds to the growing body of evidence linking coronary vasodilator function 
with adverse cardiac events by demonstrating the association between baseline coronary 
vasoreactive response with lipid content and plaque volume progression. Furthermore, 
in the context of dynamic nature of coronary atherosclerosis, LCBI may provide an 
interesting prognostic and diagnostic tool to identify patients who are at increased risk 
of future adverse cardiovascular events. Larger clinical studies are needed to explore 
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whether changes in LCBI over time may be used as surrogate for hard clinical 
endpoints.  
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Figure 1. Changes in plaque characteristics evaluated by NIRS between baseline 
and follow-up. (Red = LRP negative; Yellow = LRP positive) 
 
Figure 2. Relationship between baseline coronary vasodilator function and changes 
in lipid rich plaque (LRP) between baseline and follow-up. (Top) Segments which 
progress to contain LRP exhibit greater vasodilator dysfunction when compared to 
those which remains LRP negative at follow-up. (Bottom) 40% of segments with LRP 
at baseline “healed” during follow-up and demonstrated no significant difference in the 
baseline vasodilator function. SLV, segmental lumen volume; *p < 0.05; #p > 0.20 
 
Figure 3. Representative Images of Serial IVUS/NIRS at Baseline and Follow-Up. 
At baseline, this negative LRP segment had blunted coronary endothelium-dependent 
vasoreactive response. At follow-up imaging, it “progressed” to become LRP positive. 
MLA, minimum lumen area; PAV, percent atheroma volume. 
 
Figure 4. Forrest plot summarizing the univariate predictors of LRP at follow-up.  
 
Figure 5. Comparison between lipid progression (∆LCBI > 0) versus non-
progressor (∆LCBI ≤ 0). SLV, segmental lumen volume; PAV, percent atheroma 
volume; EEM, external elastic media; RI, remodelling index (calculated as EEM at 
follow-up -  EEM at baseline).
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Figure 1.  
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Figure 5.  
 
 


































































Table 1. Clinical, angiographic, and biochemical characteristics. 
Clinical Characteristics n = 33 patients 
Age 60.8 ± 9.13 
Female 14 (42%) 
Clinical Presentation:  
Stable (smooth coronaries) 20 (61%) 
Stable (with culprit) 3 (9%) 
ACS 10 (30%) 
Artery:  
Left anterior descending 19 (58%) 
Left circumflex 11 (33%) 
Right coronary artery 3 (9%) 
Current smoking 20 (60%) 
Diabetes 8 (24%) 
Hypertension 25 (76%) 
Hyperlipidaemia 25 (76%) 
Medications:  
Aspirin 28 (85%) 
ACE inhibitors / ARB’s 23 (70%) 
Statins 24 (73%) 
Calcium channel blocker 5 (15%) 
Nitrate 1 (3%) 
Total cholesterol (mmol/L) 4.6 [3.6-5.0] 
Low density lipoprotein cholesterol 
(mmol/L) 
2.60 [2.2-3.4] 
High density lipoprotein cholesterol 
(mmol/L) 
1.1 ± 0.3 
Triglyceride (mmol/L) 1.6 ± 1.03 
C-reactive protein (mg/L) 4.6 [0.8-9.2] 
Brain natriuretic peptide (ng/L) 98 [50-254] 
Data are expressed as mean ± SD or median [interquartile range] when appropriate. 
ACS, Acute Coronary Syndrome - defined as troponin positive presentation; ACE 
Angiotension Converting Enzyme; ARB Angiotension Receptor Blocker
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Table 2. Changes of Near Infrared Spectroscopy (NIRS) findings between baseline 
and follow-up. 
LRP NEGATIVE 
(N = 412) 
Persist 
(N = 377) 
Progress 
(N = 35) 
P value 




PAV (%) 29.57 ± 1.52 34.35 ± 2.01 0.001 
 
RI 0.15 ± 0.28 
 
0.41 ± 0.37 0.32 
 









N = 108 
Persist 
(N = 65) 
Healed 
(N = 43) 
P value 
SLV (mm3) 74.38 ± 7.32 79.01 ± 7.54 0.357 
 
PAV (%) 42.59 ± 2.51 38.6 ± 2.67 0.097 
 
RI -0.09 ± 0.4 -0.08 ± 0.42 0.99 
 
EEM (mm2) 14.45 ± 1.21 14.32 ± 1.24 0.87 
 
LCBI 326 [288-386] 235 [219-291] 0.002 
 
Data are expressed as mean ± SEM or median [interquartile range] 
LRP, lipid rich plaque; SLV, segmental lumen volume; PAV, percent atheroma volume; 
RI, remodelling index; EEM, external elastic media; LCBI, lipid core burden index; RI, 
Remodelling index    
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Table 3. IVUS and NIRS data at baseline and follow-up 
 





83 ± 13.47 69 ± 13.47 0.074 
 Median 
 
0 [0-113.5] 0 [0-85]  
 Change 
 
-13.31 ± 7.45 (mean) 0 [-25.75-0] (median)  
PAV (%) Mean 
 
31.11 ± 1.77 32.13 ± 1.77 0.068 
 Median 
 
31.5 [22.59-39.68] 31.4 [23.14-40.50]  
 Change 
 
1.02 ± 0.56 (mean) 0.66 [-2.01-3.87] (median)  
EEM (mm2) Mean 15.54 ± 0.94 
 
15.61 ± 0.94 0.73 
SLV (mm3) Mean 92.17 ± 6.48 
 
92.57 ± 6.52 0.82 
Value are expressed as mean ± SEM or median [interquartile range] 
SLV, segmental lumen volume; PAV, percent atheroma volume; EEM, external elastic 
media; LCBI, lipid core burden index. 
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Table 4. Baseline predictors of the change in LCBI in 2-mm coronary segments. 
 
 Univariate Multivariate 






p     
∆SLV 
(GTN) 
-0.84 -3.45 1.77 0.529     
LDL-C -2.12 -22.11 17.87 0.835     
Change 
LDL-C^ 
5.53 -17.54 28.59 0.639     
Change 
HDL-C^ 
-102.90 -207.5 1.69 0.054     
CRP 0.70 -7.67 9.06 0.870     
BNP 0.18 -0.44 0.80 0.566     
Total 
cholesterol 







∆SLV (salb) -3.17 -6.57 0.23 0.069 -3.03 -5.81 -0.25 0.033 
LCBI -4.35 -4.95 -3.75 0.000 -5.10 -5.75 -4.46 0.000 
PAV -4.77 -9.95 0.41 0.072 12.65 7.80 17.51 0.000 
RI^ 6.74 -0.06 13.54 0.053 6.36 0.77 11.95 0.026 
Clinical 
presentation 
-26.15 -73.51 21.22 0.289 -36.63 -81.0 7.75 0.106 
SLV, segmental lumen volume; PAV, percent atheroma volume; LCBI, lipid core 
burden index; RI, remodelling index; LDL-C, low density lipoprotein cholesterol; HDL-
C, high density lipoprotein cholesterol; CRP, c-reactive protein; BNP, brain natriuretic 
peptide; GTN, glyceryl trinitrate. ^variable incorporating baseline and follow-up data
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Table 5. Baseline predictors of the change in PAV in 2-mm coronary segments. 
 Univariate Multivariate 




p     
∆SLV (salb) 0.04 -0.11 0.20 0.581     
PAV -0.1 -0.30 0.19 0.657     
RI^ 0.08 -0.24 0.39 0.634     
LDL 0.11 -0.85 1.06 0.829     
Change in  
LDL^ 
0.48 -0.63 1.58 0.398     
Change in 
HDL^ 
-0.8 -5.96 4.38 0.765     
CRP -
0.03 
-0.43 0.37 0.875     
BNP -
0.02 
-0.05 0.01 0.212     






∆SLV (GTN) 0.18 0.06 0.30 0.004 0.21 0.09 0.33 0.0005 
LCBI 0.06 0.03 0.10 0.0002 0.07 0.04 0.10 <0.0001 
Clinical 
presentation 
1.12 -1.25 3.49 0.353 1.03 -1.51 3.58 0.426 
SLV, segmental lumen volume; PAV, percent atheroma volume; LCBI, lipid core 
burden index; RI, remodelling index; LDL-C, low density lipoprotein cholesterol; HDL-
C, high density lipoprotein cholesterol; CRP, c-reactive protein; BNP, brain natriuretic 
peptide; GTN, glyceryl trinitrate. ^variable incorporating baseline and follow-up data 
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CHAPTER 6: CONCLUSION AND FUTURE DIRECTIONS 
	
We performed a number of experiments utilizing OCT, IVUS, and NIRS in order to: (i) 
evaluate the fundamental relationship between coronary atheroma volume and 
composition with segmental coronary vasoreactive function in vivo and, (ii) to assess 
the impact of this dynamic relationship on coronary atherosclerosis progression over 
time. The key findings of these investigation are summarized below: 
• Salbutamol-mediated epicardial coronary vasoreactivity is dependent on shear 
stress generated by the coronary microvascular driving force and further 
influenced by the conduit lumen size. Owing to this observation, careful 
consideration needs to be given when evaluating human coronary endothelial 
function using OCT.  
• In coronary endothelial function assessment, adequate dosing of coronary 
vasoactive agent of choice is critical to achieve appropriate, accurate, and 
desirable conduit response, irrespective of whether assessing coronary 
endothelial dependent or independent vasomotor response. 
•  In the cross sectional analysis, atheroma plaque volume inversely correlates 
with segmental coronary epicardial endothelial independent function 
irrespective of patients’ systemic risk factors and their clinical presentation. 
Furthermore, certain ‘vulnerable’ plaque phenotype, such as lipid rich necrotic 
core appears to show an inverse association with coronary endothelial 
independent function.  
• In contrast to the previously validated studies, we found a lack of association 
between segmental coronary endothelial dependent function (in response to 
salbutamol) with either atheroma plaque volume or lipid rich plaque burden. We 
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suggest the reason for this observation is more related to dosing issue rather than 
innate biological interaction. 
• In our serial imaging study, we observed the dynamic nature of the natural 
history of human coronary atherosclerosis whereby some atheroma plaque 
appears to progress and evolve into plaque with necrotic, lipid laden core, whilst 
others ‘healed’. This transformation seems to occur at the plaque composition 
rather than the atheroma volume.  
• Irrespective of patients’ clinical presentation and baseline demography, coronary 
endothelial function predicts progression of atheroma plaque in a unique 
manner. Whereas baseline coronary endothelial dependent function predicts 
lipid content progression, segmental endothelial independent vasoreactivity 
predicts atheroma volume progression. 
• The presence of NIRS derived lipid rich plaque, measured quantitatively with 
LCBI within coronary segments at baseline imaging were significantly 
associated with both plaque volume and lipid content evolution over time.  
 
These findings have several possible clinical implications. Collectively, these data 
demonstrated that in the prospective analysis using serial intravascular imaging studies, 
the combination of ‘functional’ and ‘morphological’ data from each epicardial coronary 
segment may add significant prognostic information on how that particular conduit 
segment behaves over time. Our studies also validate previous observation on the 
inherent heterogeneity of conduit coronary segments, suggestive that in addition to 
systemic and traditional risk factors, there are also local environmental milieu, such as 
impaired vasodilating ability, which are responsible for the segmental arterial 
vulnerability, and in turn, increases the propensity of that segment to develop necrotic, 
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lipid laden core plaque, and adverse cardiac event in the future. This thesis adds to the 
growing body of evidence from prior studies which demonstrated prognostic utility and 
association between coronary endothelial dysfunction and future adverse coronary 
event. Secondly, our ability to demonstrate a vasomotor signal with GTN, a readily 
available drug in the catheterization lab, in the coronary endothelial function assessment 
both during single time point and serial intravascular imaging study potentially offer an 
attractive option for a simpler and more straightforward pharmacological agent in the 
coronary endothelial function evaluation in vivo. These observations may also resurrect 
the old debate concerning the appropriateness of routine use of the term endothelial 
‘dependent’ and ‘independent’ function versus the suggestion to redesignate the term 
‘endothelial dysfunction’ to ‘nitric oxide resistance.’ The findings from our cross 
sectional data appear to support the latter hypothesis. Third, the ability of NIRS derived 
LCBI, a quantitative measure of lipid core, to predict both coronary atheroma volume 
progression and future fibroatheroma formation independently of baseline clinical 
presentation, risk factors, and traditional IVUS grey-scale derived plaque burden 
present us with a lipid biomarker which may become a novel surrogate measure for 
coronary disease burden, and cardiovascular mortality and morbidity. Evidently, a 
larger prospective, serial imaging study would be needed to validate this hypothesis. 
The combined imaging of IVUS and NIRS offers a compelling option for detailed 
coronary plaque evaluation given its practicality, ease of use, and real time data 
generation. In contrast to other imaging modality, such as VH-IVUS or OCT which 
require some qualitative interpreting skills for lipid core detection, NIRS parameter 
measurements are fully automated, quantitative, and ready to be incorporated in the 




In spite of advances which have been made in the area of intravascular imaging, current 
strategies for evaluating coronary artery as a means for primary cardiovascular 
prevention still suffer from lack of specificity and accuracy. Consequently, we still need 
to rely on the already established risk factor calculator to determine the patient’s 
likelihood to develop future coronary event although this methodology also possess a 
number of limitations. Equally important, there remains the dilemma in fully translating 
and demonstrating prior knowledge from post mortem human studies or animal studies 
into the in vivo natural history of human coronary atherosclerosis. Therefore, future 
research needs to tackle the following: 
• Extending the observation relating to the prognostic utility of NIRS derived 
LCBI and its changes over time in a larger serial imaging and prospective study. 
Ideally, the serial imaging would need to be conducted at several time point in 
order to gain more comprehensive insights concerning the natural history 
progression of coronary atheroma. This is crucial to validate whether NIRS 
parameter measurement may yield a reliable surrogate measure for 
cardiovascular mortality and morbidity over standard plaque volume 
measurement. 
• Improving the diagnostic capability of currently available IVUS and/or OCT 
platform by refining the far field and near field resolution to create a ‘gold 
standard’ intravascular imaging device. 
• Designing and conducting large scale simultaneous examination of coronary 
endothelial function and atheroma plaque volume and/or composition non-
invasively either as a cross-sectional or longitudinal study. 
	 166 
•  Given the invasive nature of IVUS, NIRS, and OCT, it is essential to validate 
the findings from these imaging trials with their non-invasive imaging 
modalities equivalent (such as computed tomography and magnetic resonance 
imaging) with the view to generate a standardized approach of plaque analysis 
and practice guidelines for non-invasive evaluation of human coronary 
atheroma.  
• The dynamic nature of human coronary atheroma progression is not limited only 
to the epicardial coronary tree but also involving the coronary microcirculation. 
Indeed, this ‘compartment’ has been thought to play a critical role as a 
proverbial canary in a coal mine and dysfunction in this part of coronary tree is 
evident prior to the onset of angiographic coronary disease. Yet, to this date, 
there is still considerable lack of imaging modality (invasive or non-invasive) 
with direct visualization capability of in vivo human coronary microcirculation. 
Accordingly, the pivotal task of the cardiology researchers is to develop imaging 
platform and research design which can accurately analyse the integrity of the 
entire human coronary tree. 
 
All things considered, the major objective of the series of studies presented in this thesis 
is to decipher the prospective key participants in the in vivo pathogenetic mechanisms 
of human coronary atherosclerosis, with special emphasis on atheroma architecture and 
vessel function. Greater translational work ahead is desperately needed to develop a 
fuller understanding on natural progression of coronary atheroma so better prevention 
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